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Abstract 
 
Background 
Chronic Kidney Disease (CKD), has a high and increasing burden in sub-Saharan 
Africa. Environmental factors that have been associated to CKD are associated with 
multiple co-morbidities such as hypertension, diabetes, and HIV.  Some genetics 
factors such APOL1 have been associated with the highest burden of CKD among 
population of African ancestries. Other emerging genetic factors such as Sickle Cell 
trait (SCT) have been investigated mostly among African Americans. Sickle Cell trait 
(SCT) has the highest burden in sub-Saharan Africans, because of a natural selection, 
attributed to its protective advantages against the severest form of Malaria, caused by 
Plasmodium falciparum. Many studies showed that SCT has an impact on the normal 
functioning of the kidneys among African Americans with some studies indicating 
significant association between SCT and CKD. However, no study has been reported 
from Sub-Saharan Africa, where most SCT carrier reside. Moreover, there are multiple 
other loci and variants in the genome that have been associated with CKD in many 
populations, and that are used for Polygenic Risk Score (PRS) models but have not 
been explored in populations living in Africa. 
Aims 
This project aimed to study in a sub-Saharan African cohort, the association between 
1) Sickle cell trait (SCT) with Chronic Kidney disease (CKD), and 2) the association of 
CKD with 29 targeted single nucleotide polymorphisms (SNPs) identified in multiple 
Genome-Wide Association studies (GWAS).  
Methods 
Patients and controls: 300 Cameroonian adult participants were included: 150 CKD 
cases and 150 non-CKD age, sex, and comorbidities matched controls.  
Molecular methods: SCT heterozygosity was determined by RFLP-PCR using the 
restriction enzyme DdeI. A total of 29 targeted SNPs was genotyped using MassArray 
and TaqMan techniques, followed by Sanger sequencing in a subset of samples.  
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Statistical Analysis: Descriptive statistics and logistic regression, and Fisher exact test 
were used. Functional pathway analysis: following the identification SNPs with 
significant association with CKD, we performed functional pathway test using the Linux 
programme Cytoscape. 
 
Results 
 
The mean age of cases was 53 years (range 46-55 years), with 43% that were female; 
there were no age and sex significant differences with controls. We identified, an 
expected, association between CKD and various co-morbidities, demographic and 
anthropometric variables: hypertension (p value = 5.16X10-9), HIV (p value = 2.68x10-
9), diabetes (p value = 7.12X10-7), BMI (p value = 4.58X10-8) and age (p value = 
4.5X10-8). 
HbAS carrier status was significantly associated CKD (p value= 4.3X10-9; Odds 
Ratio:7.05).  Only three targeted   SNPs (3/29) previously associated with CKD in 
GWAS among African Americans, European and Asian population, were significantly 
associated with CKD among this group of Cameroonians (KBTBD2 rs3750082, 
PTPRO rs7956634 and LPR2 rs4667594 with p values of 0.02335, 0.0408 and 
0.0398). Genes protein-protein interactions analysis identified the two key functional 
pathways and one network cluster that could play a crucial role in kidney dysfunctions. 
Lastly, we distinguished that HbS carrier state doesn’t influence the relationship 
between APOL1 G1/G2 risk alleles and CKD (p value = 0.5725) in this group from sub-
Saharan Africans. 
 
Conclusion and perspectives 
 
Our study illustrates a strong association between SCT and CKD, an important 
discovery that will have a major implication in preventative medicine policies and 
practices in both sub-Saharan African where there is a very high prevalence of SCT.  
The data also has global resonance, with the projected increase in the prevalence of 
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individual with SCT, due to migration and the improve life expectancy and genetic 
fitness of people living with both SCT and SCD. 
We identified a relatively low proportion of (3/29) of target SNPs positively associated 
with CKD among this group of Cameroonians. The study illustrates that the vast 
majority of targeted SNPs associated with CKD in GWAS studies in multiple 
populations including African American, Europeans, and Asians, are not relevant for 
sub-Saharan Africans, indicating the urgent need to include diverse populations, 
specifically those living in Africa.  Therefore, the data support the  possible bias in 
currently available Polygenic Risk Score generated from GWAS data, where 
population from sub-Saharan Africa are largely underrepresented. The data further 
indicate that there is potential to discover new loci associated with CKD when 
investigating populations of African ancestry living in Africa.   
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CHAPTER 1: Introduction  
 
Chronic kidney disease (CKD) is defined as abnormalities in kidney functions or 
structure, which occurs for a duration of >3 months (Sharma 2013).  CKD can be 
categorised into five stages based on how optimally the kidney function (Table 1). The 
stages are determined by laboratory techniques, most commonly used is the 
estimated glomerular filtration rate (eGFR) calculation. 
Table 1: Different stages of chronic kidney disease 
CKD Stage Description Possible symptoms eGFR (mL/min/1.73 m2) 
Stage 1 Minimal kidney 
dysfunction 
 90–120 
Stage 2 Mild-moderate kidney 
dysfunction 
Typically, No symptoms  60–89 
Stage 3 Moderate-severe kidney 
dysfunction 
 30–59 
Stage 4 Severe kidney 
dysfunction 
Complications such as anaemia, 
(hypertension) and abnormal blood 
levels of Vitamin D, phosphorus and 
calcium 
16–29 
Stage 5 (End 
Stage Renal 
Disease 
(ESRD)) 
Complete kidney failure  Fatigue associated with anaemia, 
decreased appetite, nausea, 
vomiting, increased potassium, 
abnormalities in hormones related to 
bone health, increased phosphorus 
and/or decreased calcium, 
hypertension, and shortness of 
breath 
15 or less 
 
Mortality rates associated with CKD are staggeringly high: following the adjustment for 
gender, age, co-morbidity, prior hospitalization and race, the mortality in patients with 
CKD in 2009 was 56% higher than individuals without CKD. The adjusted mortality 
rate for Individuals with stage 4-5 CKD is estimated to be above 76% (United States 
Renal Data System. 2017 Annual Data Report. Available at 
http://www.usrds.org/adr.aspx. Accessed: January 8, 2018). Specifically, Among 
Africans than Caucasian population, mortality is higher, particularly in men than in 
women (United States Renal Data System. 2017 Annual Data Report. Available at 
http://www.usrds.org/adr.aspx. Accessed: January 8, 2018). A study by Schold et.al 
(2011) conducted within individuals that receive kidney transplants illustrated that the 
rate of acute rejection and graft loss is higher within African populations when 
compared to Caucasian populations (Schold et al. 2011). Important differences were 
also noted in a study conducted on 419 children aged between 1- 16 years. Their 
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cohort consisted of 285 Caucasian children, 67 African-Americans, 67 from a 
multiracial background and they illustrated that glomerular diseases are much more 
prevalent within African population as compared to other ethnicities explored (Wong 
et al. 2009). CKD appears to be more common in boys, this is due to the posterior 
urethral valves, which are the most common birth defect causing CKD 
(https://emedicine.medscape.com/article/238798-overview  Accessed January 8, 
2018). 
Both environmental factors that are associated with multiple co-morbidities such as 
hypertension, diabetes, and HIV have been associated to CKD (Bruce et al. 2009; 
Tonelli et al. 2015) . Of note, APOL1 has been associated with the highest burden of 
CKD among population of African ancestries (Friedman et al. 2011; Foster et al. 2013; 
Limou et al. 2014; Kruzel-Davila et al. 2016). Other emerging genetic factors such as 
Sickle Cell trait (SCT) have been investigated mostly among African Americans 
(Derebail et al. 2010; Hicks, Carl D. Langefeld, et al. 2011; Rakhi P. Naik et al. 2014).  
 
The renal medulla is characterised as an acidic environment, with hypertonicity and 
extreme hypoxia (Steinberg & Embury 1986; Kiryluk et al. 2007). When blood flows 
through the medullary vasa recta, the hyperosmolar milieu causes dehydration of 
erythrocytes resulting in the erythrocyte sickling and most probable vaso-occlusion 
and medullary microinfarctions (Van Eps et al. 1970). Micro-infarcts that develop in 
the kidney’s renal medulla and can lead to the inability to concentrate urine because 
of glomerular hyperfiltration, leading to proteinuria and glomerulosclerosis (Sears 
1978; Hostetter 2003; Kiryluk et al. 2007). Sickle Cell trait (SCT) has the highest 
burden in sub-Saharan Africans, because of a natural selection, attributed to it 
protective advantage against the severest form of Malaria, caused by Plasmodium 
falciparum (Aidoo et al. 2002; Williams, Mwangi, Wambua, Alexander, et al. 2005; 
Williams et al. 2012). Many studies showed that SCT has an impact on the normal 
functioning of the kidneys among African Americans with some studies indicating 
significant association between SCT and CKD (Rakhi P Naik et al. 2014; Burnham-
Marusich et al. 2016). However, no study has been reported from Sub-Saharan Africa, 
where most SCT carrier lives. Moreover, there are multiple other loci and variants in 
the genome that have been associated with CKD in many populations, and that are 
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used for Polygenic Risk Score (PRS) models (Vega & Bustamante 2018) but have not 
been explore in populations living in Africa. 
Assessment of the populations publicly available in Genome-wide association studies 
(GWAS) databases have revealed a clear, and significant underrepresentation of non-
European populations (Rosenberg et al. 2010). A query of the Research Portfolio 
Online Reporting Tools (RePORT) (Internet resource 1) yielded 2 267 NIH funded 
GWAS studies, of which ~14% (317 studies) concentrated of the African American 
population. Additionally, query of PubMed resulted in 4 942 publications, of which ~3% 
(148) is attributed to African American population (Peprah et al. 2015). The 
underrepresentation of African ancestry populations in GWAS is of extreme 
consequence as genetic variation have illustrated significant frequency variation 
across populations, including the frequency of the risk allele, causal and correlated 
variants along with prevalence of the disease. Significant differences have been noted 
within the  genetics determinants of disease and their effect size when comparing the 
European and non-European populations (Rosenberg et al. 2010).  
Moreover, GWAS conducted in European population have frequently failed replication 
in non-European populations (Simón-Sánchez & Singleton 2008; Turner et al. 2008; 
Mu et al. 2010). GWAS has discovered genetic variants linked with susceptibility for 
several different traits and disease conditions including asthma (IGSF3, HPSE2, 
PSAP, ATG3, MKLN1, XPR1, ABI3BP, KLHL5), cancer, obesity, hypertension 
ALDH1A2, ADH7), blood pressure (RSPO3, PLEKHG1, FAM46A, C6orf37, EVX1, 
HOXA, ULK4, SOX6, CYB5R2, SEC16B, ADCY3, GNPDA2, FTO, GALNT10, 
KLHL32, MIR148A, NFE2L3, MC4R, TMEM18) and malaria 
(HBB,SCO1,DDC,ATP2B4,ABO,MARVELD3) in recent African-ancestry populations. 
Thus, advocating for the need to increase GWAS conducted with large African 
population. 
This project aimed to study in a sub-Saharan African cohort, the association between 
1) Sickle cell trait (SCT) with Chronic Kidney disease (CKD), and 2) the association of 
CKD with 29 targeted single nucleotide polymorphisms (SNPs) identified in multiple 
Genome-Wide Association studies (GWAS).  
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CHAPTER 2: Literature review 
 
2.1 Kidney functions and Kidney disease in Africa 
 
2.1.1 Normal Kidney Function 
 
The kidneys are bean-shaped organs that are situated behind the peritoneum of the 
vertebral column (Figure 1). Humans have two kidneys on each side of their bodies. 
Each kidney weighs approximately 150g and measures 12cm in length. The kidneys 
consist of a hilus, which is a small slit that allows the renal vein, renal artery, renal 
nerve, and the lymphatics passage into the kidney and includes the renal pelvis. 
Dissection of the kidney shows two distinct regions, the cortex which is the paler inner 
region and the medulla which is the darker outer region. The renal pelvis opens up to 
the renal pyramids which houses the collecting ducts, loops of Henle and vasa recta 
(blood vessels) which gives the kidney the observed striation pattern appearance (Lote 
2013). 
              
Figure 1: Diagram of the Kidney. Illustrating the different regions and 
components of the kidney. Adapted from: http://hydr-8.com/drink-your-
water-to-flush-your-kidneys/ 
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The kidneys are responsible for maintaining the environment within the body, through 
the regulation of water, sodium, potassium, pH, minerals, blood pressure and 
haemoglobin. All waste material accumulated within the body is filtered out and 
excreted by the kidneys as urine (Rayner et al. 2016). The kidneys are also 
responsible for regulating the production of erythrocytes by producing the hormone 
erythropoietin, regulating blood pressure by secreting the enzyme renin and regulation 
of calcium absorption by activating vitamin D (Shier et al. 2009). 
Kidney function can be determined by measuring the levels of serum creatinine, by 
measuring the by-product creatinine that is produced from tearing and wearing of 
muscles. Serum creatinine level greater than 1.2 for females and 1.4 for males is 
indicative that the kidneys are not functioning optimally. Another test used to measure 
kidney function is the estimated Glomerular Filtration Rate (eGFR), which is a test that 
measures how well the kidneys are excreting waste products. The calculation is based 
on individual serum creatinine level, age, and sex. The normal value for eGFR is above 
90. Kidney function can also be monitored by measuring Blood Urea Nitrogen (BUN), 
which measures the urea nitrogen produced from the breakdown on protein. Normal 
BUN levels are between 7–20 (NFK, 2017 Available from 
https://www.kidney.org/atoz/content/kidneytests). 
Less invasive procedure for measuring kidney function include urinalysis, which 
determines the components within the urine such as protein, albuminuria, and 
creatinine clearance. Increased protein levels in the urine are indicative of kidney 
dysfunction. The kidney can also be visualized using CT scan and ultrasound to 
determine any structural abnormalities. The most invasive procedure would be to 
collect a biopsy of the kidneys to evaluate their function (NFK, 2017 Available from 
https://www.kidney.org/atoz/content/kidneytests). 
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2.1.2 Burden and aetiology of Kidney diseases in Africa  
 
Globally, an estimated 1.2 million people died from kidney failure (which is an increase 
of 32% from 2005)(GBD 2015 DALYs and HALE Collaborators 2016). In 2010, an 
approximated 2.3 –7.1 million people with end-stage kidney disease (ESKD) died 
without admission to chronic dialysis (Liyanage et al. 2015). Furthermore, each year, 
1.7 million people are assumed to die as a result of acute kidney injury. Overall, 5 –10 
million people die from kidney disease each year (Mehta et al. 2015). 
Africa is the second largest continent in the world, where it harbours a population of 
approximately 1 billion people (United Nations 2015). Epidemiologic studies have 
illustrated that the incidence of kidney diseases is higher in the developing countries 
than developed countries. There is projections illustrating that by 2030 over 70% of 
patients with ESKD are estimated to be living in low-income countries (Naicker 2003). 
Kidney disease, particularly glomerular disease, is more prevalent in Africa and 
appears to be more severe form than kidney disease found in Western countries 
(Naicker 2003).   Studies have demonstrated that individuals of African ancestry are 
at a higher risk for developing CKD, with the prevalence of CKD higher in the SSA 
population that in North Africa, which is nearly two times higher than in the general 
population (Kiberd & Clase 2002; Peralta et al. 2010).  
The known causes of CKD are hypertension (Rao et al. 1984; Botdorf et al. 2011; 
Segura & Ruilope 2011), diabetes (Villar et al. 2007; US Renal Data System 2013; 
Liyanage et al. 2015), Human Immunodeficiency Virus (HIV) (Fabian & Naicker 
2009; Lucas et al. 2014; Liyanage et al. 2015) and Body Mass Index (BMI) (Gelber 
et al. 2005; Ejerblad et al. 2006; Lu et al. 2014; Herrington et al. 2017). For sub-
Saharan Africa, projections for the year 2030 forecast that 18 -65 million people will 
have diabetes and forecasts for obesity and hypertension are similarly distressing 
(Wild et al. 2004; Kearney et al. 2005; Haslam 2007). Considering this projection in 
the context of CKD, they clearly illustrate the how the burden of CKD will drastically 
increase, especially in the African populations. Additionally, developing countries 
are also affected by poverty-related factors such as lack of water supply, infectious 
diseases, environmental pollutants and high concentrations of disease-transmitting 
vectors (Jha et al. 2013).  
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2.2.1 Familial clustering and Heritability of CKD  
 
Studies have revealed that CKD aggregates in families suggesting that the disease 
has a genetic component, although environmental exposure is still important. A study 
conducted within an African-American cohort in North Carolina illustrated a fivefold 
increase in the risk of CKD in an individual with first- or second-degree relatives who 
have CKD. The risk increased to nine-fold higher when the individuals are limited to 
those with first-degree CKD relatives (Freedman 1999). Familial clustering within the 
European population is lower when compared to the African population (Steenland et 
al. 1990; Spray et al. 1995). The risk of CKD in first degree relatives of European 
dialysis patients increased to 3-fold compared with the general population (Spray et 
al. 1995). 
Majority of kidney disease are not hereditary; however, some conditions have known 
inherited genetic components such as autosomal dominant polycystic kidney 
disease, tuberous sclerosis, Alport syndrome, and  Von-Hippel Lindau Syndrome. If 
these disorders are present within the family, the individual has increased chances of 
inheriting the disease (Available from https://www.northshore.org/personalized-
medicine/medical-genetics/hereditary-conditions/other-conditions/ Accessed January 
2019. 
 
2.2 Genetics of kidney disease in Africans 
MYH9 and APOL1 and kidney diseases 
Genetic factors involved in the development of kidney disease indicate significant 
predictors in the Myosin Heavy chain 9 (MYH9) gene within African Americans (Kao 
et al. 2008), Hispanic-American (Behar et al. 2010) and Europeans (O’Seaghdha et 
al. 2011). However, indicated no associative role of MYH9 polymorphisms within 
non-diabetic CKD patients from the Nigerian and South African population (Matsha 
et al. 2012; Tayo et al. 2013). Although, linkage disequilibrium structure may explain 
the lack of association illustrated within the African population.  
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It is estimated that the Apol1/MYH9 locus can explain up to 70% of the differences in 
ESRD rates between European and African Americans (Cavanaugh & Lanzkron 
2010).  The APOL1 nephropathy risk variants are under positive selection within the 
African continent due to the protective mechanism that they offer against the 
trypanosomal infection, similarly to the natural selection of the sickle variant (Hicks, 
Carl D Langefeld, et al. 2011).  Although a study by (Naik et al. 2015) illustrated that 
the association of SCT with CKD appeared to be independent of APOL1 risk variants. 
A significant association between Apolipoprotein L1 (APOL1) polymorphisms and 
non-diabetic kidney disease has been clearly demonstrated in various studies (Behar 
et al. 2011; Wasser et al. 2012; Fine et al. 2012; Foster et al. 2013; Genovese et al. 
2013; Ulasi et al. 2013; Colares et al. 2014; Estrella et al. 2015; Kasembeli et al. 2015; 
Parsa et al. 2013; Geard et al. 2017), following the preliminary findings reported in 
African Americans (Tzur et al. 2010; Genovese et al. 2010). The risk is witnessed in 
the presence of two copies of the risk alleles (homozygous or compound 
heterozygous) when compared to none or one APOL1 risk variant (Tzur et al. 2010; 
Genovese et al. 2010). 
HMOX1 and Kidney diseases  
Additionally, Heme oxygenase 1 (HMOX1) which forms the rate-limiting step in the 
breakdown of free haem (Tenhunen et al. 1968), with a GT-dinucleotide repeat 
(rs3074372), two promoter polymorphisms, and a nucleotide polymorphism (SNP) 
(rs743811), is associated with CKD, particularly in patient affected by sickle cell 
disease (Bean et al. 2012; Saraf et al. 2015). 
 
2.2.2 Sickle cell disease and Sickle cell trait and CKD 
Sickle cell disease (SCD) is a monogenic, multisystem disease, linked to progressive 
organ damage and acute illness (Weatherall et al. 2005). This haematological disorder 
results from a point mutation (T>A) on the sixth codon of the Beta-globin gene, located 
on the 11th chromosome (Chr11:5227002) (Sebastiani et al. 2005; Brousseau et al. 
2007). The resulting mutation on the HbS gene causes polymerization and 
precipitation of haemoglobin when exposed to deoxygenated or dehydrated 
conditions. This initiates a cascade of events starting with the sickled erythrocytes, 
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followed by, haemolysis, inflammation, abnormal adhesion of leukocyte and platelets, 
and hyper-coagulation, which can result in vaso-occlusive crisis (VOC), hypoxia and 
eventually organ damage (Lozano et al. 2010; Bartolucci & Galacteros 2012).  
Sickle Cell Trait (SCT), alternatively, is a heterozygous condition, which results from 
an individual inheriting a single pathogenic copy of the sickle cell gene (HbS) along 
with another the wildtype allele for normal haemoglobin (HbA). The compound effect 
of heterozygotes such as haemoglobin S/beta-thalassemia (Sβthal) and sickle cell 
haemoglobin C disease, exhibit a milder course when compared to the homozygous 
form (HbSS) (Schneider et al. 2016).  Individuals with SCT exhibit a tri-modal 
distribution of HbS levels, based on how many α-globin chains are deleted (Brittenham 
et al. 1985; Tripette, Loko, et al. 2010).  
 
2.2.2.1 Epidemiology of Sickle Cell Trait 
 
SCT affects an estimated 300 million people worldwide. In 2012 in the USA, 7.31% of 
African, 0.3% Caucasian and 0.22%  Asian newborns were born with SCT (Goldsmith 
et al. 2012; Taylor et al. 2014). However, the highest prevalence of SCD and SCT is 
observed in individuals of African descent residing in Africa, particularly in areas 
endemic for malaria (Figure 2).  
Nigeria has the highest number individuals affected with SCT at a prevalence of 25–
30%.  The central African countries of Cameroon and Gabon have a prevalence of 19 
and 20%, respectively (Ama et al. 2012; Elguero et al. 2015), while Ghana, Liberia, 
and Uganda have a prevalence of 10-15% each (Baffour et al. 2015; Tubman et al. 
2016; Ndeezi et al. 2016). The increased prevalence of SCD and SCT in European 
and North American countries is mainly due to the migration of individuals from Africa 
to other countries. Globally, the overall migrations increased from 92.6 million in 1960 
to 165.2 million in 2000 (Özden et al. 2011). However, within the same time period, 
the number of migrants with HbS increased from 1.6 million in 1960 to 3.6 million in 
2000 (Piel et al. 2014).  
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The burden of the carrier state is on the rise in the European countries, where an 
estimated 1% of the population harbours the sickle variant. This increase is 
hypothesized to occur as result of the global migration patterns (Modell et al. 2007) 
and has resulted in the initiation of neonatal screening programmes in European 
hospitals, thus allowing early detection and treatment (Bain 2009).    
 
 
 
SCT erythrocytes contain approximately 40% HbS, where HbA contribute to the 
remaining balance (Brittenham et al. 1985; Tripette, Loko, et al. 2010). The HbA 
significantly reduces the possibility of polymer formation, by weakening the effect of 
the HbS (Brittenham et al. 1985; Tripette, Loko, et al. 2010). Haematological 
parameters of HbS carriers are largely normal - particularly the size and shape of the 
erythrocyte, Hb levels and the reduced or complete lack of intravascular haemolysis. 
Even as some mild abnormalities manifest, they are usually considered subclinical 
(Tripette, Loko, et al. 2010). 
A robust association has been illustrated between the frequency of the HbS and the 
incidence of malarial infection (Charache et al. 1992; Williams, Mwangi, Wambua, 
Alexander, et al. 2005). The association was first reported by Allison in 1954, where 
he first suggested the protection offered by SCT against the severest form of malaria, 
Plasmodium falciparum (Allison 1954). The protection offered by SCT against malaria 
is thought to be responsible for the continuous presence of the trait within malaria-
endemic regions of the world (Elguero et al. 2015).  
Figure 2: Graphical representation of Global burden of SCD. The highest burden is 
witnessed within the African continent, particularly in area endemic with malaria. Adapted 
from (Piel et.al 2013) 
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Williams et.al (2005) clearly illustrated the protective effect of the SCT against malaria. 
They conducted a study where they inoculated 30 individuals with Plasmodium 
falciparum (15 individuals with SCT and 15 without SCT). They noted that 14 of 15 
individuals without SCT developed malaria, in contrast to only 2 of 15 individuals with 
SCT developed malaria (Allison 1964; Wilcox et al. 1983; Williams, Mwangi, Wambua, 
Peto, et al. 2005; Hill et al. 2016). Correspondingly, the rate of complicated falciparum 
malaria cases requiring immediate hospitalization reduced by a staggering 90% within 
individuals with SCT (Williams, Mwangi, Wambua, Alexander, et al. 2005). 
There are 4 possible mechanisms proposed on how SCD and SCT offer protection 
against malaria:  1) Reducing the growth of the parasite within the erythrocyte; 2) 
Reduced invasion and development of Plasmodium falciparum within the erythrocytes; 
3) Stimulation of the innate immune system; and/or 4) Heightened clearance of 
parasitized erythrocytes by the spleen (Williams, Wambua, et al. 2005; Derebail et al. 
2010; Gong et al. 2012; Taylor et al. 2013). SCT protection offered against malaria is 
only specific for P. falciparum and not the other 3 types of malaria (Plasmodium ovale, 
Plasmodium malariae and Plasmodium vivax) (Williams, Mwangi, Wambua, 
Alexander, et al. 2005). The protection offered by SCT will increase with age, 
beginning at 20% at the age of two years and increasing to a maximum of 56% at the 
age of 10 years (Williams, Mwangi, Wambua, Alexander, et al. 2005). It will however 
eventually decrease to 30% at ages above 10 years (Williams, Mwangi, Wambua, 
Alexander, et al. 2005). 
 
 
2.2.2.2 Genetics of SCD 
 
Haemoglobin is a tetrameric molecule consisting of two pairs of polypeptide subunits 
(Figure 3). The heterotetramer consists of two α-like globin genes which are located 
on chromosome 16, and two β-like or γ –like globin genes which are located on 
chromosome 11. During foetal phase of development, the major type of haemoglobin 
produced is HbF (α2γ2), it is at this point that most haemoglobinopathies go undetected 
and undiagnosed (Bank 2006). The main haemoglobin within adult humans is a 
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heterotetramer termed haemoglobin A, which consists of two α-globin and two β-globin 
polypeptides, along with haem-group (Hardison 2012).  
                             
 
 
 
The SCD mutation, in haemFoglobin, was first identified by Pauling and his colleagues 
in 1949 (Pauling et al. 1949). Their work was corroborated and followed-up by Ingram 
et. al in 1959, where they characterized the mutation as a single point mutation which 
resulted in a glutamine-to-valine substitution at the sixth residue of the β-globin peptide 
(Ingram 1959). The SCD mutation results from a single nucleotide base change; 
whereby it is a monogenic condition; however the clinical manifestation exhibited by 
the patients are complex, and can range from early childhood mortality to an almost 
undetectable condition where patients survive to late adulthood (Sebastiani et al. 
2005; Bartolucci & Galacteros 2012). The phenotype is highly influenced by the other 
genetic variants, particularly the deletion of the α-globin chains. The relationship 
between the genotypic and phenotypic relationship is illustrated in Table 2. 
  
Figure 3:  Structure of the haemoglobin molecule. Haemoglobin comprises of two β-globin 
(green) and two α-globin (purple) chains. The SCD mutation is located on the β-globin chain. 
Adapted from (Schechter et.al 2008) 
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Table 2: Genotypes and phenotypes of sickling disorders. 
Genotype Interacting 
Genes 
Typical 
Severity 
% of Hb/total Hb in a typical patient 
HbS (%) HbA (%) HbF (%) HbC (%) HBA2(%) 
HbAA β and β  None - 96 2 - 2 
HbSS βs and βs Severe 95 - 3 - 2 
HbSC βs and βc Mild 48 - 3 47 2 
HbSβ0 βs and β0 Severe 93 - 2 - 5 
HbSβ* βs  and β* Moderate 85 6 5 - 4 
HbSβ* βs  and β* Mild 70 23 3 - 2 
*HbAA- Normal haemoglobin 
*HbC- Haemoglobin C 
*HbF- Foetal haemoglobin 
*HbSC- Haemoglobin SC disease 
*HbSβ0- Thalassemia 
*HbSS- Sickled haemoglobin 
 
Vaso-occlusive crises (VOC) is the main clinical manifestation of adult SCD and it is 
characterised by intense bone pain (Bartolucci & Galacteros 2012). Clinical 
manifestations that are considered very severe include stroke, haemolytic anaemia, 
cardiovascular disease, pain, acute chest syndrome, priapism, hypertension, 
nephropathy and pulmonary hypertension hypoxia leading to kidney dysfunctions 
(Lozano et al. 2010; Bartolucci & Galacteros 2012). Whether Kidney dysfunctions, 
observed in SCD, is also prevalent in people with sickle cell trait have been 
controversial in the literature, and is the focus of this dissertation. 
 
2.2.2.3 Sickle Cell Trait and Chronic Kidney Disease (CKD) 
 
Kidney diseases are estimated to affect 5 -18% of patient with Sickle Cell Disease/Trait 
(Ashley-Koch et al. 2011). Studies have illustrated that renal impairment can affect 4-
20% of SCD patients (Herrick 1910; Guasch et al. 2006), while CKD can affect 
approximately 60% of SCD patient (Guasch et al. 2006; Saraf et al. 2014). CKD 
impacts all races; however, individuals of African ancestry are more affected. End 
Stage Renal Disease (ESRD) among African individuals in the USA is approximately 
4 times that of the Caucasian population. The highest estimated eGFR is witnessed 
within the African population is approximately 45-59 mL/min/1.73 m2  (Hicks, Carl D 
Langefeld, et al. 2011). 
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The environment within the kidney is characterised as an acidic environment, with 
hypertonicity and extreme hypoxia (Steinberg 1986; Kiryluk et al. 2007). When blood 
flows through the medullary vasa recta, the hyperosmolar milieu causes dehydration 
of erythrocytes resulting in the erythrocyte sickling and probable vaso-occlusion and 
medullary microinfarctions (Van Eps et al. 1970). Micro infarcts that develop in the 
kidney’s renal medulla can lead to the inability to concentrate urine as a result of 
glomerular hyperfiltration, leading to proteinuria and glomerulosclerosis  (Sears 1978; 
Hostetter 2003; Kiryluk et al. 2007). 
The medullary infarcts are accompanied with papillary necrosis, which is associated 
with both microscopic and macroscopic haematuria (presence of blood in urine) and 
hyposthenuria (impaired urinary conetration) (Van Eps et al. 1970; Gupta et al. 1991; 
Key & Derebail 2010). In most cases, the left kidney is more involved due to its slightly 
larger size and higher venous pressure and as a result of compression from the left 
renal vein by the superior mesenteric vein and aorta (Mitchell 2007; Connes et al. 
2008; Tsaras et al. 2009). In a study by (Heller et al. 1979), macroscopic haematuria 
occurred in both SCD and SCT individuals where it affected approximately 4% of their 
African American SCT patients.  
A study conducted by Key et.al (2010) estimated the prevalence of SCT within 188 
African-American End Stage Renal Disease (ESRD) patients on dialysis. 
Approximately 15% (28 of 188) of the patients were found to have SCT. Their data 
suggest that SCT exerts an influence on renal disease. Moreover, the patients with 
SCT were on dialysis for a longer duration. Their findings were supported by another 
study which used a cohort of 5319 patients on haemodialysis, were they noted a  
prevalence of 10.2% (543) patients with SCT (Derebail et al. 2014). Additionally, 
African-American individuals with SCT exhibit two times the prevalence of ESRD than 
individuals without SCT (Derebail et al. 2010).  
In contrast, a case control study by Hick et.al (2011), involving a cohort of 2081 African 
Americans with ESRD and 1177 controls without ESRD, illustrated no difference 
among those with ESRD when compared to those without (Hicks, Carl D Langefeld, 
et al. 2011). Similar findings illustrating the association of SCT and CKD  were noted 
within the Latino and Hispanic with a Caribbean background population (Kramer et al. 
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2017; Dueker et al. 2017), however, this finding could not be replicated within the 
Democratic Republic of Congo population (Mukendi et al. 2015). 
The largest study conducted on the association of SCT and Renal disorders was 
published in 2014 in the Journal of the American Medical Association (JAMA) on 15 
975 patients, of African American descent, of which 1248 had SCT. Their results 
illustrated an increased risk of renal diseases in patients with SCT. The SCT patients 
illustrated a higher risk for developing diabetic complications when compared to those 
with normal haemoglobin (Ajayi & Kolawole 2004; Rakhi P Naik et al. 2014). However, 
some literature (Bleyer et al. 2010; Ama et al. 2012), shows evidence that suggests 
that there is no link between SCT and DM or any CKD. 
A comparative study by Aloni (2017) reported on glomerular function in children with 
SCT to children with SCD and healthy children. Their study indicated a significant 
increase in blood pressure levels when comparing children with SCT and SCD, a 
moderate decline in eGFR when comparing SCT and SCD patients, increase in 
hyperfiltration in SCT children although to a lesser extent in SCD children, in 
comparison to their healthy counterparts. However, in all cases, proteinuria was not 
detected. No significant difference was seen when comparing uric acid levels in SCT 
children to healthy children, but the uric levels were lower when in SCT children 
compared to SCD children. The difference may be due to haemolytic processes 
occurring in both the SCT and SCD children. The increased hyperfiltration was 
assumed to result from the HbS polymerisation. This data correlated to previously 
published literature (Al-Naama et al. 2000). 
SCT has been hypothesized to play a role as a possible pathophysiological condition 
resulting in lower blood pressure (Aloni et al. 2017). The lower blood pressure is 
assumed to be due to vasodilation, as a counter measure against hypoxia. The cause 
of the lower blood pressure is still unknown.  
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2.2.2.5 Other targeted genes variants from Genome-Wide Association Studies 
(GWAS) SNPs that associated with CKD. 
Other genomic variants in multiple genes have been associated with kidney functions. 
For instance variants in the FGF23 gene, when associated with elevated levels of 
FGF-23 are independent factor for ESRD within patients with adequate kidney function 
(Isakova et al. 2011). Sixteen SNPs within the SHROOM3 gene have also been 
associated eGFR, along with the development of albuminuria (Ellis et al. 2012). A 
genome-wide association study (GWAS) including over 130 000 participants found six 
SNPs involved in decreased GFR, located in or near, DDX1, INO80, CDK12, 
SLC47A1, CASP9, and MPPED2 (Pattaro et al. 2012).  
Several genes which have been associated with ESRD development, involve aspects 
of the immune system (CCR3, IL1RN, IL4) and RAS genes, with patients more likely 
to  develop A2350G SNP in the angiotensin-converting enzyme (ACE) gene and the 
C573T polymorphism in the angiotensin II type 1 receptor (AGTR1 gene) (Su et al. 
2012). 
Presently, the role of the polymorphisms in the apolipoprotein E (apoE) (Lahrach et 
al. 2014), endothelial nitric oxide synthase (eNOS) (Salimi et al. 2006; Kerkeni et al. 
2009), xeroderma pigmentosum group D (XPD) (Radwan et al. 2015) , X-ray repair 
cross-complementing protein 1 (XRCC1) (Radwan et al. 2015),  renalase (Rezk et al. 
2014), adiponectin (ADIPOQ)(El-Shal et al. 2014) and C-C chemokine receptor type 
2 (CCR2) (Sezgin et al. 2011) genes in the aetiology of CKD remains debated and 
further investigation in a larger African studies should be conducted to validate these 
results.  
 
Of a particular note, Pattaro et al. (2016) performed a GWAS meta-analysis in 133 
413 individuals from European, Asian and African ancestry. Initially, they determined 
the phenotype definitions by measuring the serum creatinine and establishing a 
diabetes diagnosis criterion. CKD was defined as eGFRcrea 60ml min-1 per 1.73m2. 
Genotyping was performed using a wide array of NGS platforms (Illumina and 
Affymetrix 500K), followed by logistic regression to adjust for sex and age using the 
program METAL (Pattaro et al. 2016).  
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Replication analysis was performed using eight independent studies, whereby the 
index study having an established genomic-wide significance of 5.0 X 10-8.   The t-test 
was used to determine the difference between the SNP effect on eGFRcrea in 
diabetes versus the non-diabetes groups. A similar analysis was performed to 
compare results in subjects with and without hypertension. Pathway analyses were 
performed using a novel program DEPICT to prioritize genes at associated loci and to 
test whether these genes are highly expressed in specific tissues or cell types. It was 
further used to test whether specific biological pathways and gene sets are enriched 
for genes in associated loci (Pattaro et al. 2016). 
Pattaro et.al (2016)’s study confirmed 29 previously identified loci and identified 48 
novel single nucleotide polymorphisms (SNPs). From the 48 SNPs, only 21 were 
genome-wide significant (P< 5.0 X 10-8). The 48 SNPs were tested for any 
associations with related phenotypes and very little association was demonstrated 
between 24 novel SNPs with other kidney-related traits. Only one SNP (PTPRO 
rs7956634) was significant in the African Ancestry, whereas seven SNPs (IGFBP5 
rs2712184, SKIL rs9682041,UNCX rs10277115,APB5B1 rs4014195, PTPRO 
rs7956634, KCNQ1 rs163160, SIPA1L3 rs11666497) showed significance in the 
Asian populations (Pattaro et al. 2016).  
In the present study, in addition to exploring the association to SCT, we have examined 
SNPs in 29 loci in a cohort of patients with CKD from Cameroon. The nominated loci 
were selected based on the following criteria: 1) they appear to be associated with a 
genome-wide significance (P value <0.06), with kidney functions in all three of the 
previously mentioned populations i.e. African Americans, Europeans, and Asians; 2) 
these variants where also all confirmed in a trans-ethnic analyses and meta-analyses 
in which all replicated loci were included (Table 3), but yet explored among sub-
Saharan Africans living in Africa. 
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Table 3: List of SNPs investigated in the patients and controls cohorts 
 
Loci dbSNP Chromosome location Alleles Proven disease associations (Ensembl) 
UMOD rs4293393 16:20353266 C/T Chronic Kidney Disease 
ANXA9 rs267734 1:150979001 A/G Chronic Kidney Disease 
GCKR Rs1260326 2;27508073 C>T Chronic Kidney Disease 
TFDP2 rs347685 3:142088295 A/C Chronic Kidney Disease 
DAB2 rs11959928 5:39397030 A/T Chronic Kidney Disease 
VEGFA rs881858 6:43838872 A/G Chronic Kidney Disease 
ATXN2 rs653178 12:111569952 A/G Celiac Disease 
SLC22A2 rs2279463 6:160247357 C/T Chronic Kidney Disease 
TMEM60 rs6465825 7:77787122 C/T Chronic Kidney Disease 
SLC6A13 rs10774021 12:240132 C/T Chronic Kidney Disease 
BCAS1 rs17216707 20:54115823 C/T Glomerular Filtration Rate 
SDCCAG8 rs2802729 1:243338461 G/T Glomerular Filtration Rate 
LRP2 rs4667594 2:169151996 A/T Glomerular Filtration Rate 
SKIL rs9682041 3:170374114 C/T Glomerular Filtration Rate 
UNCX rs10277115 7:1245559 A/T Renal Function related trait 
KBTBD2 rs3750082 7:32880315 A/T Glomerular Filtration Rate 
A1CF rs10994860 10:50885664 C/T Glomerular Filtration Rate 
KCNQ1 rs163160 11:2768725 A/G Glomerular Filtration Rate 
AP5B1 rs4014195 11:65739351 C/G Chronic Kidney Disease 
PTPRO rs7956634 12:15168260 C/T Glomerular Filtration Rate 
NFKB1 rs228611 4:102640552 A/G Glomerular Filtration Rate 
CACNA1S rs3850625 1:201047168 A/G Kidney Functions 
WNT7A rs6795744 3:13865353 A/G Glomerular Filtration Rate 
SYPL2 rs12136063 1:109471548 A/G Glomerular Filtration Rate 
ETV5 rs10513801 3:186104564 G/T Glomerular Filtration Rate 
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DPEP1 rs164748 16:89641884 C/G Glomerular Filtration Rate 
LRP2 rs4667594 2:169151996 A/T Glomerular Filtration Rate 
SIPA1L3 rs11666497 19:37973622 C/T Glomerular Filtration Rate 
NFATC1 rs8091180 18:79404243 A/G Glomerular Filtration Rate 
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RATIONAL 
Studies on the impact of SCT on CKD has been limited, particularly in African 
countries, where the most severe impact of CKD is seen within African countries. 
There have not any study reported in Cameroon.  Moreover, there are multiple other 
loci and variants in the genome that have been associated with CKD in many 
populations, and that are used for Polygenic Risk Score (PRS) models but have not 
been explored in populations living in Africa.  Ultimately, the identifications of genomic 
variants that could affect kidney functions will help in developing a genetic risk model, 
that will inform anticipatory guidance in clinical practice.  
 
Aim 
This project aims to study the association between Sickle cell trait (SCT) and 29 
targeted single nucleotide polymorphisms (SNPs) identified in multiple GWAS studies 
with Chronic Kidney disease (CKD) in an African Cohort. 
 
Objectives 
 
1. To Clinically describe an existing cohort of patients with CKD of various etiology 
and ethnically controls 
2. To Perform SCD diagnosis using Polymerase Chain Reaction (PCR) followed 
by restriction enzymes fragment length polymorphism (RFLP) using the 
enzyme Dde1 
3. To Genotype 29 SNPs that are associated with CKD using MassArray and 
TaqMan techniques, and Sanger Sequencing 
4. To Determining the differential frequency obtained for both SCT and the 29 
SNPs by comparing CKD patients and healthy controls   
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CHAPTER 3: Methods and Materials 
 
In this chapter, we will be introducing all the methodology performed for this study. 
 
3.1 PATIENTS’ DATA 
3.1.1 Ethical Approval 
 
The study was performed according to the principle of the declaration of Helsinki 
(Gandevia & Tovell 1964; Ebihara 2000). Ethical approval for this study was granted 
by the University of Cape Town, Faculty of Health Sciences Human Research Ethics 
Committee (HREC RE: 661/2015) and the National Ethical Committee Ministry of 
Public Health, Republic of Cameroon (No 033/CNE/DNM/07).  
 
3.1.2 Participants' descriptions 
 
We used  biological samples of an existing cohort of 150 with CKD patients recruited 
in Yaoundé and Douala, Cameroon, with  the available following information: socio-
demographic data (family history,  age, sex, and ethnicity), Anthropometric variables 
(Body Mass Index, Systolic Blood Pressure (SBP) and Diastolic Blood Pressure 
(DBP)),  kidney biological functions and  the stage of Kidney disease; and the  Co-
morbidity associated with CKD (High Blood pressure (HBP), Diabetes mellitus, HIV, 
Lupus).  The control cohort comprised of age, sex, and co-morbidity (HBP, Diabetes 
Mellitus), and an ethnically matched group of 150 control volunteers. 
 
3.2 MOLECULAR METHODS 
3.2.1 Samples Preparation 
 
Available DNA samples were previously extracted from the peripheral, using salting 
our methods, at the University of Yaoundé 1.  The DNA purity and concentration were 
assessed using a NanoDrop® ND-1000 Spectrophotometer (Wilmington, USA). The 
device operated using NanoDrop® Spectrophotometry computer software. DNA 
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quantification is based on the Beer Lambert’s law which states that the concentration 
of a sample is directly proportional to the absorption of light by the sample. The 
principle follows the formula outlined below: 
    A = ε.b.c 
The A260: A280 ratio is used to establish the purity levels of the sample. The optimal 
ratio is ~1.8. Ribonucleic Nucleic Acid (RNA) and Deoxyribonucleic Acid (DNA) consist 
of nucleic acid which absorbs light at 260 nm. Proteins have a purity ratio of ~2.0 and 
have an absorb light at 280 nm. Often the A260: A230 ratio is used to determine if 
there is any contamination such as phenol as a result of the extraction process.  
The optimal working sample concentration is 100 ng/µl. Samples with a concentration 
above 100 ng/µl were diluted to the optimal concentration. Stock DNA with 
concentrations below 100 ng/µl was aliquoted out to produce the working solution 
without dilution. The stock DNA was returned to the -20°C freezer whilst the working 
DNA samples were stored in the 4°C fridge.  All experiments were conducted using 
the working solution. 
 
3.2.2 Primers Design 
 
The primers for a polymerase chain reaction (PCR) amplification for the SCD 
diagnosis and validation for the 29 SNPs were created using the Ensemble build 79 
(Accessed 04/05/2017 and 15/08/2017).  The ideal primers have a GC content 
between 40-60%, a length between 18 and 24 bases long and melting temperature 
(Tm) between 54-58°C. Deviation from the range results in primers with less specificity 
and stability. 
The WhiteScientific IDT OligoAnalyzer 3.1 (http://eu.idtdna.com/calc/analyzer , 
Accessed 04/05/2017 and 15/08/2017) was used to analyze the selected primer. The 
primers were blasted using the PrimerBlast® (http://blast.ncbi.nlm.nih.gov/Blast.cgi ) 
to determine any non-specific binding. The primers are described in Table 4: 
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Table 4: Tabulation for the primers used for SCD Diagnosis and validation of the genotyped SNPs 
Sequence ID Sequence 
 
Length(bp) 
GC 
content 
(%) 
Melting 
Temperature 
(Tm) °C 
 
 
Objective 
rs334_HBB_2Cut_F AGAAGAGCCAAGGACAGGTA 20 50 57.67 SCD 
Diagnosis rs334_HBB_2CUT_R GTCAGTGCCTATCAGAAACC 20 50 55.85 
rs10994860 A1CF_F ATTGGCTCCACTCTTGAACC 20 50 57.79            V
a
lid
a
tin
g
 S
N
P
s
 G
e
n
o
ty
p
in
g
 
rs10994860 A1CF_R GATTATATCTGGGCTGTAGTGACC 24 58.27 58.27 
rs881858 VEGFA_F AGAAGAGGCCCAAATATGCC 20 50 57.63 
rs881858 VEGFA_R AGGAACCTTAGAGAACAAGCG 21 47.62 57.63 
rs6795744 WNT7A_F GGAGTATAACATGCTGAGTTCCC 23 47.83 58.59 
rs6795744 WNT7A_R ACACGTGAAGAAGTGTATGGC 21 47.62 58.62 
rs7956634 PTPRO_F CAAGTCTGGCTTATGATTGCC 21 47.62 57.29 
rs7956634 PTPRO_R GGAATGGAAATTGAGTCTTTAGGC 24 41.67 58.10 
rs4293393 UMOD_F AAATACAAGGTCACTGTTTCGC 22 40.91 57.52 
rs4293393 UMOD_R AATTTATTTCGCCTCCAAAGGG 22 40.91 57.26 
rs4667594 LRP2_F AGACTGTCCTGCCTTATTTCC 21 47.62 57.36 
rs4667594 LRP2_R GGTTTGCACTGACTTACATTGG 22 45.45 58.10 
 
The primers were manufactured by Integrated DNA Technology (IDT), but supplied by 
Whitehead Scientific (Iowa, USA) in powder form and were re-suspended to 100 µM 
using TE buffer.   
 
3.2.3 Polymerase Chain Reaction (PCR) 
 
PCR is the technique used in the amplification of gene fragments, where the amplified 
product can be used for a wide range of downstream applications. The reaction 
consists of a DNA template, buffer solution, deoxyribonucleotide triphosphates 
(dNTPs), primers and Taq Polymerase. The region-specific primers bind to the DNA 
template which contains the variant of interest. The primers provide 3’hydroxyl end 
required by the Taq Polymerase during DNA polymerization, whilst the dNTPs act as 
the building blocks that are required in the synthesis of the new strand. Optimal 
reaction conditions are provided by the buffer where it offers balanced pH and salts 
(mg2+). 
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The cycling condition for the reaction was obtained using the Bio-Rad thermal cycler 
T100™ (Bio-Rad Laboratories, Hercules, CA, USA). The cycling conditions included 
5 minutes of initial denaturation at 95°C, followed by 30 cycles of 30 seconds of 
denaturation at 95°C, 30 seconds of annealing at 59°C, 2 minutes of extension at 72°C 
and a final elongation step of 7 minutes at 72°C. 
The amplified DNA fragments were visualized by 3% agarose electrophoresis. 10 µl 
of the PCR product mixed with 5 µl of loading dye (ThermoFischer) and loaded onto 
an agarose gel and electrophoresed for 45 minutes at 120V. A 100bp ladder 
(ThermoFischer) was used as the molecular weight marker as a reference lane to 
determine the size of the PCR product.  The fragments were visualised using with 1 X 
SYBR safe nucleic acid stain under UV illumination on an UVItech transilluminator. 
                          
 
 
  
MWM  95    98     100    111  116   119   120  122  123  125  128   129  130  131  
132 133 
MWM  134  135 136 137 138  139  140 141 142 143 144 145 146 147    +    -   NTC 
Figure 4: PCR Amplification of the DNA fragment containing the SCD mutation 
The image indicates PCR fragment for SCD mutation run at 160V for 1 hour on a 3% (w/v) agarose 
gel. In the first lane is the molecular weight marker (MWM), the GeneRuler™ 100bp Ladder 
(Thermo Fisher Scientific). + - positive control, - negative control, * UND indicated the undigested 
control and NTC-Non-template control. 
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3.2.4 Sickle Cell Trait Genotyping 
 
Following amplification, to confirm the heterozygosity of the sample the PCR product 
was digested using a restrictive enzyme Dde1 enzyme (Promega, USA). The PCR 
product was digested overnight at 37°C and visualized in a 3% agarose gel run for 45 
minutes at 120V. The fragments were visualised using with 1 X SYBR safe nucleic 
acid stain under UV illumination on an UVItech transilluminator 
                              
 
 
 
 
 
3.2.5. MassArray and TAQMAN® genotyping Assays for the other targeted 
SNPs  
 
From the 29 SNPs to be genotyped, 26 SNPs were sent to a service provider (Inqaba 
Biotech, Pretoria, South Africa) for genotyping with the MassArray technique. They 
were provided with 50 µl of DNA from each of the 150 CKD cases and 150 matched 
controls with a concentration of 100 ng/µl. The remaining 3 SNPs were genotyped in 
the Human Genetics laboratory, in the University of Cape Town (UCT) using the 
TaqMan® technique. MassArray protocol used by Inqaba involves the use of an initial 
locus-specific PCR reaction, followed by single base extension using mass modified 
dideoxynucleotide terminators of an oligonucleotide primer which anneals immediately 
upstream of the polymorphic site of interest. Using MALDI-TOF mass 
spectrophotometry, the distinct mass primer identifies the SNP allele 
MWM  95 98   100     111    116   119   120    121  123   125   128    129   130   
131   132  133  
MWM 134   135 136   137  138   139    140  141     +      -    *UND  NTC 
Figure 5: RFLP imaging of the SCD mutation using the DdeI enzyme 
The image illustrates the SCD mutation run at 160V for 1 hour on a 3% (w/v) agarose gel. In the 
first lane is the molecular weight marker (MWM), the GeneRuler™ 100bp Ladder (Thermo Fisher 
Scientific). + - positive control, - negative control, * UND indicated the undigested control and 
NTC-Non-template control. 
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TaqMan® involved specific and sensitive assays that detect the amplified products. 
The specificity and sensitivity are provided by targeted primers and probes in the 
assays, which come optimized for ideal functional performance on quantitative PCR. 
Detection for the Single Nucleotide Polymorphisms (SNPs) uses fluorescent signal 
probes which allow for easier detection of the polymorphisms 
TaqMan® Assay contains Taq-polymerase, two fluorophore probes that have Minor 
Groove Binder (MGB) and two region-specific primer pair (forward and reverse). The 
probes are labelled with reporter dyes (FAM and VIC) which release fluorescence 
when the reporter is cleaved off from the 5’ end releasing it from the non-fluorescent 
quencher.  
The assays were received in a stock 40X concentration and were diluted to 20X using 
1X TE buffer (0.3M EDTA and 7M Tris, pH 7.3) to prepare the working solution. A 
reaction volume of 10 µl consisted of 5 µl of 20X TaqMan® Genotyping Master Mix 
(Applied Biosystems, Thermo Fischer Scientific, Warrington, UK), 0.5 µl, of 20X 
TaqMan® Assay (Applied Biosystems, Thermo Fischer Scientific, Warrington, UK), 2.5 
µl, of nuclease-free water and 2 µl of DNA. The mix was added into each well of 96-
well plate (Bio-Rad Laboratories, Hercules, CA, USA). The cycling condition started 
with initial 10 minutes amplification at 95°C, 15 seconds denaturing at 95°C and 1-
minute annealing/extension step for at 60°C using CFX96 real-time system (Bio-Rad 
Laboratories, Hercules, CA, USA). Analysis of the data performed using the Bio-Rad 
CFX96 (Bio-Rad Laboratories, Hercules, CA, USA) Manager Software (version 3.1). 
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3.2.6 Cycle Sequencing for validation of genotyping 
 
A subset of the cohort (6 SNPs in 10% of the cohort) initially genotyped either by Mass 
Assay or the TaqMan, was validated through Sanger sequencing and illustrated in 
figure 7. Sanger sequencing is the gold standard technique for genotype validation, 
as it allows visualization of the individual base in the sequence (Sanger et al., 1977). 
A total of 10 μl reaction requires 1 μl of BigDye® Terminator v3.1 Cycle Sequencing 
mix (Life Technologies), 2 μl BigDye® Terminator v3.1 dilution buffer, 1 μl of primer 
(reverse or forward primer), 4 μl distilled Sabax water, 2 μl of the PCR product. The 
reaction mix contains four dye-labelled dideoxynucleotides (ddNTPs) which have an 
absent hydroxyl group, resulting in the termination of DNA synthesis. The sequencing 
product was precipitated by adding 50 µl of absolute ethanol and 2 µl of sodium 
acetate. Followed by, vortexing and overnight incubation at -20°, ensuring DNA 
precipitation and high yield of the DNA sequences.  
  
Figure 6: TaqMan SNP Genotyping plot for the cohort for rs881858.  The TaqMan allelic discrimination 
plot was produced using the Bio-Rad CFX96 (Bio-Rad laboratories, Hercules, CA, USA). The Y-axis 
corresponds to the (RFU) for the VIC 5’-dye label while the X-axis corresponds to the (RFU) for FAM 5’-
dye.  The FAM and VIC 5’dye corresponds to the C and A alleles, respectively. The blue squares 
represent the homozygous for the CC allele, the green triangles represent the heterozygous AC allele 
and orange circles represent the homozygous AA allele. The analysis was preformed using the Bio-Rad 
CFX96 (Bio-Rad laboratories, Hercules, CA, USA) Manager software version 3.1. 
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The sequences were vortexed, and the supernatant was discarded. The sequences 
were re-suspended in 50 µl of 70% ethanol and mixed by vortexing. This was followed 
by centrifugation for 10 minutes at 10 000g and the supernatant was discarded, and 
the sequences were allowed to air-dry. This pellet was re-suspending 10µl HiDi 
Formamide. 
The sequencing products have different fragments lengths, which are fluorescently 
labelled at the 3’end. DNA is separated by size (1bp) using capillary electrophoresis 
and fluorescently tagged ddNTPs using the 3130xl Genetic Analyzer ABI Prism 
(Applied Biosystems).  
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Figure 7: Sanger sequencing validation for rs881858 in patient 7, 10 and 15.  Electrogram produced using 
ABI Prism 3130xl Genetic Analyser (Applied Biosystems). Analysis was performed using the software 
program Chromas (Version 2.6.6) for analysis of the genotype for rs881858. (A) is the GG wildtype 
genotype for patient 7, (B) is the GA heterozygous genotype for patient 10 and (C) is the AA mutant 
genotype for patient 15 
B 
C 
A 
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3.3 Statistical Analysis 
Statistical analysis of the cohort was performed using STATA® SE-64 software 
program (version 14.0.370 for Windows).  Descriptive statistics were obtained for the 
sociodemographic data attained during recruitment. Plink (Appendix 1)(Purcell et al. 
2007) was used in the analysis of the results obtained for the SCT diagnosis and also 
the association of the targeted SNPs with CKD. Logistic regression was employed to 
examine the genetic association between SCT and CKD (p-value < 0.05) and any 
association between CKD and the targeted SNPs (p-value < 0.05), while Fischer’s 
exact test was used to examine any association with SCT and other clinical 
phenotypes (p-value < 0.05). 
Following the identification of any associated SNPs, we performed functional pathway 
test using the Linux programme Cytoscape. Cytoscape is an open source platform 
used for visualization and complex networks analysis such as networks of genes or 
interacting proteins.  
Lastly, using already available data on APOL1 (Geard et.al 2017) which illustrated no 
association with CKD in the sample cohort, we analysed the influence of SCT on the 
APOL1-CKD relationship using ODDs ratio analysis. 
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CHAPTER 4: RESULTS 
 
In this chapter, we will be presenting the results obtained from our study. 
 
4.1. Population Description and clinical phenotypes 
4.1.1 Socio-demographic and anthropometric variables and CKD 
Table 5 describes the socio-demographic and anthropometric variables of the CKD 
patients and non-CKD controls indicating most of the participants were adults with a 
mean age of 53 years (range: 46-55) and matched as designed with non-CKD controls 
with a mean age of 54 years (range: 46-61). As designed, the cohort consisted of 
equal proportions of females and males with a p-value of 0.771.  
Both the cases and control illustrated a normal distribution of BMI values, systolic and 
diastolic blood pressure with p-values of 0.00, 0.002 and 0.10 respectively. The 
diastolic and systolic blood pressure appears as above normal in the patients’ group, 
due to the associated co-morbidity, as increased BP values are expected within a CKD 
cohort. 
 
Table 5: Social-demographic and anthropometric variables and CKD 
 
Variables CKD Cases 
%(n) 
Non-CKD 
controls %(n) 
P-value 
Age(years) 53 54 0.459 
Gender Female %(Number) 28.6 (43)  30 (45) 0.771 
 Male %(Number) 71.3 (107)   70 (105) 
BMI (kg/m2) 24 29 0.00 
Systolic blood pressure(mmHg) 148 142 0.002 
Diastolic blood pressure(mmHg) 85 83 0.10 
Total Observation 150 150  
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Figure 8 illustrates the distribution of BMI and Age in CKD cases and control while 
figure 9 illustrates the distribution of the Systolic blood pressure and diastolic blood 
pressure. The BMI, age, systolic and diastolic blood pressure showed normal 
distribution for both patients and control. 
 
                      
 
               
 
   
A 
Figure 8: Histogram distribution of BMI and age in CKD cases and non-CKD controls. The 
histogram illustrates normal distribution of (A) BMI and (B) age variables within the cohort. 
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Figure 9: Histogram distribution of Systolic Blood pressure (mmHg) and Diastolic Blood 
pressure (mmHg) in CKD cases and non-CKD controls. The histogram illustrates normal 
distribution of (A) Systolic Blood pressure (mmHg) and (B) Diastolic Blood pressure (mmHg) 
variables within the cohort. 
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4.2 Validity of the statistical model used in the analysis of the cohort 
The model used in the analysis of the cohort indicates True Positive Rate (TPR) of 
approximately 1 and a precision rate of approximately 1 (Figure 10), both illustrating 
that the model used is dependable, rigid and accurate. The regression model has a 
chi-square of 281.697 with a p-value of 1.60X10-52   and the model has achieved 
accuracy and precision of 0.91 and 0.89 respectively.  
 
        
 
 
 
 
4.3 Description of CKD and other clinical co-morbidity 
The logistic regression model confirmed an association between CKD and diabetes, 
HIV and hypertension at p values of 7.12X10-7, 2.68X10-9, 5.16X10-9 respectively 
(Table 6). An association between CKD and hypertension (Table 6) was established 
with a log ODDs ratio of 8.09226 indicating that a hypertensive individual has a 
probability of 1 of developing CKD when compared to healthy individuals. The study 
also revealed an association of CKD and HIV (Table 6) with a log ODDs ratio of 8.7045 
indicating that the carrier has a probability 1 of developing CKD. Diabetes was 
associated with CKD (Table 6) at a log ODDs ratio of 6.5663 indicating that the 
individual has a probability 1 of developing CKD.  
A B 
Figure 10: Graphical representation of the validity of the model used in the analysis of the 
cohort. The TPR is approximately 1, while the precision and recall are approximately 1, indicating 
that the results obtained from the model are reliable.  
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The associated phenotypes were represented in bar graphs in figure 11. 
Table 6: Association of CKD and other clinical phenotypes 
Variables ODDs ratio P-value 
Diabetes 6.56663 7.12X10-7 
HIV 8.7045 2.68X10-9 
Hypertension 8.09226 5.16X10-9 
 
   
                                              
 
 
 
4.4 Description of the SCT within the CKD cases and non-CKD controls 
Table 7 illustrates a significantly higher frequency of AS individuals within the CKD 
cases (n=49) when compared to the non-CKD controls (n=10) with an ODDs ratio of 
7.05 and p-value of 4.371X10-9. This indicates that carriers have a 7.05 times chances 
of developing CKD when compared to controls individuals. 
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Figure 11: Bar graph representation of additional clinical phenotypes that are positively associated in 
influencing the development of CKD. A) Diabetes B) HIV and C) Hypertension 
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Table 7: Association of SCT within CKD cases and non-CKD controls. 
 
CASES %(n) CONTROLS %(n) ODDs 
Ratio 
P Value 
 
AA AS AA AS - - 
Frequencies 66 (96) 34 (49) 93 (140) 7 (10) 7.04 4.371X10-9 
 
Age (mean) 53 53 54 54 1 0.459 
Gender Female 25 (24) 97 (32) 32 (44) 10 (1) NA 
Male 75 (72) 3 (1) 68 (95) 90 (9) NA 
Family 
History 
yes   9 (9) 10 (5) 7 (10) 100 (10) NA 
No 91 (87) 90 (44) 93 (128) 0 (0) NA 
Systolic Blood 
Pressure(mmHg) 
149 149 142 145 1 0.02 
Diastolic Blood 
Pressure(mmHg) 
85           85 83 84 1 0.10 
BMI (kg/m2) 24 24 29 29 1 0.00 
 
4.5 Association between SCT and CKD 
Logistic regression (Table 8) was performed on the cohort which illustrated an 
association between SCT, BMI, Age and CKD at p values of 0.000625, 4.58X10-8 and 
0.016227 respectively. The association between SCT and CKD achieved a log ODDs 
ratio of 2.40223 indicating that a carrier has a 0.92 probability of developing CKD as 
compared to healthy individuals. The association between BMI and CKD illustrated a 
log ODDs ratio of 0.32816 indicating that the carrier has 0.58 probability to develop 
CKD when compared to healthy individuals. Age was also identified as a variable that 
influences the development of CKD at a log ODDs ratio of 0.0621 indicating that the 
carrier has a 0.52 probability of developing CKD. All the factors that were associated 
are illustrated in figure 12. 
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Table 8: Factors influencing CKD within the cohort 
Variables Z value P value 
SCT 3.421 0.000625 
Age 2.404 0.016227 
Sex 0.425 0.671162 
BMI (kg/m2) 5.467 4.58X10-8 
Systolic Blood 
Pressure (mmHg) 
-0.517 0.604984 
Diastolic Blood 
Pressure (mmHg) 
-1.238 0.215817 
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Figure 12: Graph representation of positively associated factors influencing the development of CKD. A) 
Bar graph- SCT B) Box and Whisker- Age and C) Box and Whisker -BMI 
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4.6  Description of SCT and other clinical co-morbidity 
Analysis of the cohort revealed the association of SCT and other clinical co-morbidity; 
particularly, hypertension and Human Immunodeficiency Virus (HIV); the only 
exception was diabetes which was not influenced by the SCT, illustrated in Table 8 
and figure 13. An association between SCT and HIV (Table 9) was established with a 
highly significant p-value of 0.000323 and ODDs ratio of 6.586044 indicating that the 
carrier could have  6.59 times chances of increased risk of attaining HIV when 
compared to healthy individuals. Further analysis of the cohort revealed an association 
between SCT and hypertension (Table 9) with a p-value of 0.04639 and ODDs ratio 
of 1.831774 indicating that the carrier has 1.83 times more risk of hypertension as 
compared to healthy individuals. Diabetes was the only variable not influenced by the 
SCT (Table 9) with a p-value of 0.7203 and an ODDs ratio of 1.129938 indicating no 
evidence that SCT influences diabetes state. 
Table 9: Association of SCT and other clinical co-Morbidity 
Variables ODDs ratio P-value 
Diabetes 1.129938 0.7203 
HIV 6.586044 0.000323 
Hypertension 1.831774 0.04639 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 13: Bar graph representation of clinical phenotypes influenced by the presence of SCT. A) HIV 
B) Hypertension 
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4.7 Frequencies of CKD-related genes variants across various populations 
Table 10: Allele frequencies of selected CKD-related genes variants among Cameroonian Controls and data extracted from the 1000 Genome project. 
       Gene dbSNP location Allele Cameroon African 
 
East 
Asian 
European Cameroon 
vs African P 
values 
Cameroon vs 
East Asia P 
values 
Cameroon vs 
Europe P 
values 
UMOD Rs4293393 16:20353266 A>G 0.22 0.193 0.084 0.201 0.0394 0.00001       0.0903 
ANXA9 rs267734* 1:150979001 T>C 0.009 0.069 0.026        0.194         0.0035          0.1432        0.0000 
GCKR rs1260326 2:27508073 C>T 0.005 0.094 0.481 0.411 0.7792 0.00001 0.00001 
TFDP2 rs347685 3:142088295 A>C 0.26 0.264 0.289 0.278 0.9244 0.3744 0.5765 
DAB2 rs11959928 5:39397030 A>G 0.28 0.287 0.174 0.451 0.0762 0.00001 0.0011 
SLC22A2 rs2279463 6:43838872 A>G 0.19 0.186 0.082 0.128 0.0374 0.00001 0.00001 
TMEM60 rs6465825* 6:160247357 C>T 0.44 0.493 0.780 0.574 0.2882         0.00001 0.0002 
SLC6A13 Rs10774021 12:240132 C>T 0.40 0.45 0.800         0.0185 0.0001         0.00001 0.00001 
BCAS1 rs17216707* 20:54115823 C>T 0.02 0.035 0.043 0.227         0.0185 0.0001 0.00001 
LRP2 rs4667594 2:169151996 A>T 0.37 0.521 0.865        0.488         0.0364         0.0118        0.00001 
SKIL rs9682041 3:170374114 C>T 0.26 0.290 0.060 0.121 0.0000 0.00001 0.00001 
UNCX rs10277115 7:1245559 A>T 0.21 0.116 0.308 0.754 0.0640 0.00001 0.00001 
KBTBD2 rs3750082 7:32880315 A>T 0.37 0.330 0.656 0.635 0.5725 0.00001 0.00001 
A1CF rs10994860 10:50885664 C>T 0.28 0.222 0.047 0.202 0.1577 0.00001 0.00001 
KCNQ1 rs163160* 11:2768725 A>G 0.05 0.062 0.208 0.179 0.6550 0.00001 0.2277 
AP5B1 rs4014195 11:65739351 C>G 0.28 0.263 0.237 0.351 0.3945 0.00001 0.00001 
PTPRO rs7956634 12:15168260 C>T 0.45 0.550 0.273 0.829 0.0248 0.7481 0.0042 
NFKB1 rs228611 4:102640552 A>G 0.22 0.188 0.486 0.482 0.0000 0.00001 0.00001 
CACNA1S rs3850625 1:201047168 A>G 1 0.995 0.960 0.882 0.3726 0.00001 0.00001 
WNT7A rs6795744 3:13865353 A>G 0.24 0.231 0.081 0.158 0.2274 0.0008 0.00001 
SYPL2 rs12136063 1:109471548 A>G 0.28 0.269 0.957 0.689 0.7273 0.00001 0.0140 
ETV5 rs10513801* 3:186104564 G>T 0.004 0.012 0.063 0.138 0.7086 0.00001         0.00001 
DPEP1 rs164748 16:89641884 C>G 0.08 0.064 0.016 0.477 0.2086 0.0001        0.1831 
SIPA1L3 rs11666497 19:37973622 C>T 0.06 0.061 0.110 0.195         0.2574 0.00001        0.00001 
NFATC1 rs8091180 18:79404243 A>G 0.12 0.125 0.784 0.597 0.9736 0.5448         0.1831 
IGFBP5** Rs2712184 2:217682779 A>C 0.46 0.442 0.533 0.572 0.5921 0.00001        0.00001 
VEGFA rs881858 :43838872 A>G 0.28 0.656 0.773 0.695 0.3373 0.0004        0.00001 
ATXN rs653178* 12:111569952 A>G 0.04 0.981 0.997 0.534 0.0000 0.00001        0.00001 
SDCCAG8 rs2802729 1:243338461 A>C 0.46 0.490 0.319 0.445 0.3356 
 
0.0969 0.0002 
Significant P values are bolded. dbSNP ID; single nucleotide polymorphism database identification; NA, not applicable.*     indicates monomorphic SNPS
The differential frequencies across populations of the SNPs investigated are 
presented in Table 10. A total of 10/29  SNPs  (34%) were differentially distributed  
among Cameroonian  individuals compared to  African controls from the 1000 
genomes project. Only 2/9 SNPs illustrated a significant or borderline association with 
CKD. Up to 83 % of the variants studied (24/29) were differentially frequent when 
comparing Cameroonian versus East Asian individuals with CKD (Table 10). 
Additionally, comparison with European American population illustrated a significant 
difference in allele in 22/29 (75.8 %) SNPs. 
 
4.8 Association of CKD and targeted genomic variants 
 
Five SNPs (ANXA9 rs267734, BCAS1 rs17216707,KCQN1 rs163160,CACNA1S 
rs3850625, ETV5 rs10513801 and ATNX2 rs653178) were monomorphic and further 
excluded from analysis, however, the model illustrated an association between CKD 
KBTBD2 rs3750082,PTPRO rs7956634 and LPR2 rs4667594 with p values of 
0.02335, 0.0408 and 0.0398and the 3 targeted SNPs, respectively.  
Additionally, two SNPs DAB2 rs11959928 and  UNCX rs10277115 illustrated a 
borderline association with CKD with p values of 0.08937 and 0.06895 respectively 
(Table 11). 
 
Table 11: Tabulation of the 29 targeted SNPs investigated within the cohort.  
Loci dbSNP Chromosome 
location 
Alleles Minor Allele 
Frequency 
(MAF) 
P-Values Chi-Square ODDs 
Ratio 
UMOD  rs4293393 16:20353266 C/T 0.25 0.5461 0.3643 1.132 
ANXA9 rs267734 1:150979001 A/G 0.006 0.7585 0.09451 0.6485 
GCKR Rs1260326 2;27508073 C>T 0.40 0.398 4.227 1.969 
TFDP2 rs347685 3:142088295 A/C 0.010 0.8107 0.05737 0.9534 
DAB2  rs11959928 5:39397030 A/T 0.26 0.08937 2.886 1.379 
VEGFA rs881858 6:43838872 A/G 0.34 0.6999 0.1486 1.077 
ATXN2 rs653178 12:111569952 A/G 0.24 0.1469 2.105 0.3848 
SLC22A2 rs2279463 6:160247357 C/T 0.45 0.2209 1.498 1.297 
53 
 
 
TMEM60 rs6465825 7:77787122 C/T 0.01 0.9299 0.007728 0.9847 
SLC6A13 rs10774021 12:240132 C/T 0.31 0.6625 0.1905 1.095 
BCAS1 rs17216707 20:54115823 C/T 0.24 0.2409 1.375 0.4514 
SDCCAG8 rs2802729 1:243338461 G/T 0.13 0.5167 0.4206 0.8847 
LRP2 rs4667594 2:169151996 A/T 0.28 0.333 0.9371 0.7867 
SKIL rs9682041 3:170374114 C/T 0.23 0.1056 2.619 0.7138 
UNCX rs10277115 7:1245559 A/T 0.05 0.06895 3.308 0.6591 
KBTBD2 rs3750082 7:32880315 A/T 0.25 0.02335 5.142 0.6337 
A1CF rs10994860 10:50885664 C/T 0.45 0.3036 1.058 0.8171 
KCNQ1 rs163160 11:2768725 A/G 0.21 0.3813 0.7666 0.6912 
AP5B1  rs4014195 11:65739351 C/G 1 0.5458 0.3648 0.8545 
PTPRO rs7956634 12:15168260 C/T 0.22 0.0408 4.184 1.444 
NFKB1 rs228611 4:102640552 A/G 0.26 0.8068 0.05984 0.9504 
CACNA1S rs3850625 1:201047168 A/G 0.004 NA NA NA 
WNT7A rs6795744 3:13865353 A/G 0.08 0.6032 0.2702 0.8989 
SYPL2 rs12136063 1:109471548 A/G 0.06 0.4873 0.4825 0.8711 
ETV5 rs10513801 3:186104564 G/T 0.11 0.979 0.000693 1.038 
DPEP1 rs164748 16:89641884 C/G 0.40 0.6516 0.2039 1.155 
LRP2 rs1260326 2:169151996 A/T 0.30 0.0398 4.277 1.969 
SIPA1L3 rs11666497 19:37973622 C/T 0.01 1 NA NA 
NFATC1 rs8091180 18:79404243 A/G 0.44 0.7399 0.1102 0.9152 
Significant P values are bolded. dbSNP ID; single nucleotide polymorphism database identification; 
NA, Not applicable. 
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Figure 14: Association between targeted variants and CKD (CKD Cases: panels A, C, E respectively) vs 
Control (panels B, D, F, respectively). Associated SNPs were KBTBD2 rs3750082,PTPRO rs7956634 and 
LPR2 rs466759 4 at p-values of 0.02335, 0.0408 and 0.0398, respectively. 
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4.9 Functional Pathway Analysis 
 
Following the use of the Linux programme Cytoscape, two functional pathways were 
identified which are the Advanced glycation end products (AGE or RAGE) signaling 
pathway in diabetic complication and the regulation of the receptor-mediated 
endocytosis. The AGEs comprise of a complex group of compounds which are a result 
from the oxidation and non-enzymatic glycation of nucleic acids, protein, and lipids, 
because of a pathologic condition such as hyperglycaemia or naturally through aging. 
The receptors corresponding to the AGE pathway are known as RAGE (Yamagishi 
2011). The receptor-mediated endocytosis is a mechanism in which molecules are 
engulfed into a cell.  The mechanism is based on the specificity of the receptor-ligand 
interaction.  Receptors on the membrane of the target tissue will specifically bind to 
ligands on the exterior of the cell, resulting in an endocytotic process. 
Analysis of the protein network pathways using the Gene Ontology (GO), we identified 
8 homo-candidate gene clusters (Table 12). The total number of candidate genes that 
are key protein is 1. The disease-associated key protein is cluster 2 with the NFKB1 
gene, P19838 (Figure 15).  We consider the cluster as a key genetic cluster which 
comprises of 4619 genes and key genes in key cluster interacting with the key 
candidate are 181. The main processes involved in the target sets are: cellular 
response to mechanical stimulus (GO:0071260), T cell receptor signalling pathway 
(GO:0050852), NF-kappaB signalling (GO:0038061), positive regulation of NF-
KappaB transcription factor activity (GO:0051092) and the Fc-epsilon receptor 
signalling pathway (GO:0038095). We identified enriched Kyoto Encyclopedia of 
Genes and Genomes (KEGG) pathway in which key genes are implicated, we 
managed to identify 22 pathways of interest. 
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Table 12: Tabulation of the network clusters 
Cluster Genes 
Cluster 0  SCL6A13,ATXN2,DPEP1, A1CF, SCL22A2 
Cluster 1 DAB2, TMEM60 
Cluster 2 UNCX, BCAS1, LRP2, WNT7A, SYPL2, NFKB1, VEGFA, UMOD, SKIL, 
ETV5, AP5BI, ANXA9 
Cluster 3 NFKB1 
Cluster 4 TFDP2, KBTBD2 
Cluster 5 CACNA1S,  KCNQ1 
Cluster 6 SDCCAG8,NFATC1,PTPRO 
Cluster 7 SIPA1L3 
 
 
  
Figure 14: Illustration of the NFKB1 based sub-network. The network clearly indicates the major 
role of the NFKB1 in the protein-protein sub-network. 
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4.10 Influence of SCT on the APOL1  and CKD relationship. 
APOL1 G1/G2 was previously genotype in the cohort by another investigator (Geard 
et al. 2017), and the was not significant association with CKD. We investigated 
whether  HbS carrier state can influence the association between APOL1 and CKD 
(Table 13):  we did not find a significant association (p-value = 0.5725; Odds ratio = 
1.433), indicating that there is no evidence that SCT influences the relationship 
between APOL1 and CKD. 
 
Table 13: Association of APOL1 G1/G2 and CKD, conditioned to SCT 
Gene P value ODDs Ratio 
APOL1 0.5725 1.433 
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CHAPTER 5: DISCUSSION 
 
In this chapter, we will be analysing all the results obtained from the study and their 
potential biological impact in the cohort, moreover within the population. 
 
5.1 Originality 
 
Both SCT and CKD affect a great proportion of individuals within the African 
population, however, studies on the impact of SCT on CKD have been limited, 
particularly in Africa, where most carriers live. With our current study, we aimed to 
elucidate the missing link between the impact of SCT on CKD. Additionally, we 
investigated 29 SNPs in 29 genes (Table 10), that may affect the development of CKD, 
in a group of patients from Cameroon.  
The nominated loci were selected from a recent study by Pattaro et.al (2016), based 
on the significant correlation with CKD among multiple populations i.e. African 
Americans, Asians, and Europeans, and that have also achieved a genome-wide 
significance. To the best of our knowledge, our study will be the first to look at the 
identified loci and SCT in a cohort of CKD patients living in Africa. Of particular note, 
we closely matched the socio-demographic and clinical co-morbidity between patients 
and controls (Table 5).  
 
5.2 CKD and known Clinical Comorbidities  
 
An expected, association between CKD and hypertension was found (Table 9). 
Hypertension occurs within 85-95% of patients with CKD (Rao et al. 2008; Botdorf et 
al. 2011; Segura & Ruilope 2011). Approximately, one billion people worldwide have 
hypertension and that number is expected to increase to 1.56 billion people by 2025 
(Kearney et al. 2005). Hypertension can lead to CKD because of the negative effect 
that increased BP has on kidney vasculature. Chronic hypertension can result in 
impairing glomerular filtration and high intraglomerular pressure (Yoshioka et al. 1987; 
Keane et al. 1999). The damage caused to the glomeruli results in increased protein 
59 
 
 
filtration, causing abnormally high amounts of protein in the urine known as 
microalbuminuria (presence of the protein albumin within the urine) and proteinuria 
(occurs when the protein-to-creatinine ratio is above 200 mg/g and often develops with 
the progression of CKD) (Yoshioka et al. 1987; Keane et al. 1999). 
The study also revealed an expected association of CKD and HIV (Table 9). HIV is a 
huge burden within Africa, with approximately 24.7 million people within sub-Saharan 
Africa affected (Joint United Nations Programme on HIV/AIDS 2013; Stanifer et al. 
2014; World Kidney Day 2016; GBD 2015 DALYs and HALE Collaborators 2016). 
Approximately, 3.4 million South Africans living with HIV are receiving Antiretroviral 
Therapy (ART) (Islam et al. 2012) and the numbers are expected to increase over 
time. Kidney disease is an acknowledged complication of HIV infection affecting 
3.5 – 48.5% of individuals (Fabian & Naicker 2009; Lucas et al. 2014). Kidney 
diseases have moved from the 27th to the 18th most important global cause of death 
in the last twenty years (Liyanage et al. 2015). The link between CKD and HIV was 
first reported in New York in 1984 (Rao et al. 1984). Kidney diseases associated to 
HIV can be caused by the HIV virus as it enters the kidney or alternatively by the side 
effects of the medication which can be lactic acidosis, crystals, interstitial nephritis and 
electrolyte abnormalities (Available at https://www.davita.com/education/kidney-
disease/risk-factors/hiv-aids-and-chronic-kidney-disease Accessed 24/08/2019). Risk 
factors that can lead to CKD are African ancestry, diabetes, CD4 count <200 cells/µL, 
unsuppressed viral load, family history of CKD, hypertension, and HCV infection 
(Available at https://www.hiv.va.gov/provider/manual-primary-care/renal-disease.asp 
Accessed 24/08/2018). 
Diabetes was associated with CKD (Table 9). Globally, an estimated 171 million 
people are affected with diabetes (Wild et al. 2004) with a projected growth reaching 
up to 642 million people by 2040 (International Diabetes Federation (IDF) et al. 2015). 
Additionally, an estimated 39 330 000 of individuals with diabetes present with 
moderate to severe CKD (Coresh et al. 2003; Middleton et al. 2006; American 
Diabetes & American Diabetes Association 2011). Diabetes has been illustrated as 
the leading cause of End-Stage Kidney Disease (ESKD)  and this trend expected to 
grow over time especially in developing countries (Villar et al. 2007; US Renal Data 
System 2013; Liyanage et al. 2015). The development of CKD from diabetes results 
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from the increased sugar levels within the bloodstream damaging the small blood 
vessels throughout the body including the small vessels within the kidney (Available 
at: https://www.davita.com/education/kidney-disease/risk-factors/diabetes-is-the-
leading-cause-of-chronic-kidney-disease Accessed 24/08/2018).  
In the present study, and as expected, we also found an association between BMI and 
CKD. Our results correlate with studies from some authors in many different 
populations (Gelber et al. 2005; Ejerblad et al. 2006; Lu et al. 2014; Herrington et al. 
2017). Increasing BMI was also associated with CKD in sickle cell disease in African 
populations (Asnani et al. 2016; Geard et al. 2017). However, no association between 
BMI and CKD was found in a study in Taiwan (Chang et al. 2018),  and a  Caucasian 
population from USA (Brown et al. 2012). The link between BMI and CKD can be 
hypothesized to result from obesity and increased weight being predisposing factors 
for developing various chronic diseases (Pinkowish 1998). Arguably, BMI is not a 
reliable factor for assessing risk in CKD, since the CKD patients usually suffer from 
fluid retention and BMI fails to account for it (Navaneethan et al. 2016). 
Age, as expected, was also identified as a variable that influences the development of 
CKD. It has been previously established that eGFR declines the older an individual 
becomes (Davies & Shock 1950), even in SCD (Asnani et al. 2016; Geard et al. 2017). 
Within the Chinese population, it was noted that the females aged between 18-39 
years have a 7.4% prevalence of CKD, while females aged 60-69 have 18% and 
females aged 70 have a 24.2% prevalence of CKD (Zhang et al. 2012). Similar results 
were illustrated in USA (Coresh et al. 2007), Canada and Europe (Zhang & 
Rothenbacher 2008; Arora et al. 2013). However, the risk of developing CKD when 
aging may also be due to the normal age-associated decline in kidney function which 
is not attributed to other unknown factors (Zhou et al. 2008). 
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5.3 Association of the SCT within the CKD cases and non-CKD controls 
 
The association between SCT and renal dysfunctions has been highly debated with a 
several publications showing contradicting data (Rakhi P. Naik et al. 2014). Few 
publications found the association, particularly with regards to hyposthenia and 
haematuria (Gupta et al. 1991). The present study has revealed a strong association 
between SCT trait (HbAS individuals) with CKD cases; this is a novel finding on a 
population living in sub-Saharan Africa, where SCT is highly prevalent and could reach 
a prevalence of more than 25% in country such Nigeria and DRC (Ezenwosu et al. 
2015; Burnham-Marusich et al. 2016).  
These findings could have a major implications in public health and clinical practice 
and in health policy, there are potentially nearly hundreds of millions of individuals with 
SCT in sub-Saharan Africa, that could benefit from counseling for CKD, including life 
style preventive measures , to avoid  developing exacerbating co-morbidity such HBP, 
diabetes or HIV. Our findings correlate with a few available literature from African 
American studies (Key & Derebail 2010; Derebail et al. 2014) and within Latino and 
Hispanic individuals with a Caribbean background (Dueker et al. 2017; Kramer et al. 
2017). However, the SCT and CKD was not found in populations living in the 
Democratic Republic of the Congo population (Mukendi et al. 2015), that could be 
attributed to the difference in the size, sociodemographic and with the present 
Cameroonian cohort. The development of CKD within SCT individuals was 
hypothesized to be caused by sickled erythrocytes resulting in vaso-occlusion and 
medullary microinfarctions within the kidneys. Resulting in inhibition of urine 
concentration whilst leading to proteinuria, glomerulosclerosis and glomerular 
hyperfiltration (Van Eps et al. 1970; Sears 1978; Hostetter 2003; Kiryluk et al. 2007).  
Discovery of association between HbAS and CKD can be used in the therapeutic 
management of CKD. Individuals already known to suffer from CKD, especially 
individuals with African ancestry, need to genotype for SCT for appropriate 
counselling.  
 
  
62 
 
 
5.4 Beyond association with CKD, SCT is not that benign 
 
The present results support other emerging data that indicate that SCT is not a benign 
condition as previously thought. Multiple disorders have now been associated with 
SCT, including  rhabdomyolysis (Harmon et al. 2012), vaso-occlusive crisis (Tripette, 
Connes, et al. 2010) and medullary carcinoma (Alvarez et al. 2015). Individual fitness 
most likely impacts the progression of rhabdomyolysis. Improving exercise conditions,  
oxidative stress and inflammation may reduce the rapid progression of the disease 
(Chirico et al. 2012; Aufradet et al. 2010). The acidic environment and decreased 
venous partial pressure of oxygen (PO2) that develops within the kidney may be 
contributors to the pathophysiology of rhabdomyolysis. Debatable, the presence of the 
sickled erythrocyte may exert a strain to vessels within the striated muscle resulting 
muscular deterioration (Harmon et al. 2012).Over the duration of 2000- 2010, there 
has been an increase in African American participants for the National Collegiate 
Athletic Association (NCAA) college football league. An approximated 22 892 of 
African American athlete have joined the league within that period. Assuming that  the  
prevalence of SCT is ~7% this can indicate that about 1 602 of the enrolled participants 
may be in risk of developing rhabdomyolysis (Eichner 2010). These results illustrate 
the probability of how many individuals may be SCT carriers and advocates for better 
understanding of the disease, thus allowing the development of guidelines in the 
detection, treatment and ultimately the prevention of rhabdomyolysis. 
Medullary carcinoma has been noted in individuals of all ages but predominantly in 
younger patients with SCT or SCD at the age below 40 (Davis et al. 1995; Coogan et 
al. 1998; Warren et al. 1999; Watanabe et al. 2007). The association between SCT 
and medullary carcinoma is a strong robust association, without much literature to the 
contrary. Individuals with SCT are highly at risk for the development of medullary 
carcinoma, thus early prevention through early screening for SCT is essential. There 
is a great need for a better understanding of the genetics and molecular factors 
influencing the development of medullary carcinoma, enabling the development of 
promising therapies. 
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The mechanism of vaso occlusion (VOC) in SCT patients, is a more complexed 
process than anticipated and may comprise multiple receptor-ligand pairs expressed 
on at least three cell types (Frenette 2002) such as leukocytes.  The intensity of the 
VOC depends on how many alpha-globin genes deleted (Steinberg 1986; Piel et al. 
2013). In most cases, HbAS take up 40% of the globin within erythrocyte, any 
exposure to adverse conditions such as dehydration and hypothermic environment 
can lead to the sickling of erythrocyte, although to a lesser extent than in HbSS 
(Brittenham et al. 1985; Tripette, Loko, et al. 2010).  
 
 5.5 Description of possible SCT and other clinical phenotypes 
We also found an association between SCT and a few clinical conditions that should 
be interpreted with caution, as they could be hugely biased by our cohort selection 
confounded by multiple co-morbidities. However, the data suggest that these findings 
could deserve additional investigations, in the general populations. For example, an 
association between SCT and HIV (Table 8) was found. Nevertheless, several case-
reports that indicate that SCD (although not SCT) slows the progression of  HIV and 
hypothesized that this association can elucidate new ideas in HIV treatment (Nouraie 
et al. 2012; Obaro 2012; Owusu et al. 2015). Several credible explanations were 
established for this observation, including reduced HIV viral replication because of the 
insistent up-regulation of inflammation, immunologic changes and iron metabolism 
common in SCD individuals. Researchers illustrated that the white blood cells within 
SCD patients have a resistance mechanism against HIV-1 infection because of how 
the iron is metabolized in SCD patients (Kumari et al. 2016). However, there is no 
publicly available data on the association between SCT and HIV. 
Further analysis of the cohort revealed an association between SCT and hypertension, 
that could be due to the selection bias of this group of patients that is not representative 
of the general populations (Table 8). No data was publicly available on the association 
of SCT and hypertension. 
 
Diabetes was not associated with SCT in the present study (Table 8). Our data 
correlates with studies by (Bleyer et al. 2010; Ama et al. 2012; Rakhi P Naik et al. 
64 
 
 
2014) which  show evidence that suggest that there is no link between SCT and DM, 
but contradicts studies by (Ajayi & Kolawole 2004; Goldsmith et al. 2012) were SCT 
patients illustrated higher risk for diabetic complications when compared to those with 
normal haemoglobin. A recent 2018 study indicated SCT as a possible risk for the 
development of T2D-related complications. Their cohort numbers, particularly the 
individuals which are SCT carriers,  were greater than our cohort, which might explain 
the contradicting data (Skinner et al. 2018). 
 
5.6 Association of CKD and targeted genomic variants 
 
This is the first study to explore multiple SNPs associated with CKD and consistently 
replicated in many world populations, in an African Cohort. We found that five SNPs 
(ANXA9 rs267734, BCAS1 rs17216707,KCQN1 rs163160,CACNA1S rs3850625, 
ETV5 rs10513801, and ATXN2 rs653178) were monomorphic, indicating that only one 
allele occurs at the locus in the population (Elston et al. 2017). This is an important 
finding as it indicates that African Americans data, used in the previous study and that 
shown association with genome-wide significance with these SNPs, are not proxy for 
African living in Africa. Indeed, African ancestry in self-declared African American can 
range from 1- 99% with an average of 70% (Campbell & Tishkoff 2008; Gomez et al. 
2014). Moreover, up to 10 SNPs also show a significant difference between our control 
group and African data extracted from the 1000 genome project, demonstrating the 
highest genetic diversity found in Africans living in Africa.  
The data supports and  emphasizes as much as possible using controls from the same 
population background, because in the same African country even regional difference 
might be massive (Lambert & Tishkoff 2009). In addition, that major difference in MAF 
when comparing these SNPs with data from European (75.8%) and Asians (83%), 
support that risk model developed for CKD, will be largely uninformative in populations 
of African ancestry. It is also a call to improve diversity in GWAS studies globally, 
which are still overpowered by studies in a population of African ancestry (Peprah et 
al. 2015), and in Africa in particular, thus improving and attaining a polygenic risk score 
that can be universally used (Vega & Bustamante 2018). 
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Surprisingly, only 3/29 SNPs Gene- KBTBD2-rs3750082,PTPRO-rs7956634 and 
LRP2-rs4667594 were associated with CKD at a p-values of 0.02335, 0.0408 and 
0.0398, respectively (Table 10). These results support the need to perform GWAS 
studies for CKD in populations living in Africa, indicating that there is a potential to 
discover novel loci not found in other world populations.  SNP rs3750082 is in the 
Kelch Repeat and BTB Domain Containing 2 (KBTBD2) gene, SNP rs7956634 is 
found within the Protein Tyrosine Phosphatase Receptor Type O (PTPRO) gene while 
SNP rs4667594 is in the low-density lipoprotein-related protein 2 (LRP2) gene. All 
three SNPs are intronic variants associated with glomerular filtration rate within the 
kidneys, eluding to their potential to be pathogenic especially if they occur on the 
intron-exon junction or regulator site of the gene. These SNPs have only been cited 
once in a study conducted by Pattaro et.al 2016 and colleagues where they indicated 
KBTBD2 rs3750082 (p-value 2.52X10−7), PTPRO rs7956634 (p-value 2.46X10-9) and 
LRP2 rs4667594 (p-value 2.37X10−7) as novel SNPs associated with eGFR within 
individuals of European ancestry. Only SNP PTPRO rs7956634 was associated with 
other kidney-related traits within the African population (Pattaro et al. 2016). 
Two SNPs DAB2 rs11959928 and UNCX rs10277115 illustrated a borderline 
association with CKD with p values of 0.08937 and 0.06895. SNP DAB2 rs11959928 
is an intergenic variant located in the Clathrin Adaptor Protein, where it encodes for 
the mitogen-responsive phosphoprotein. SNP UNCX rs10277115 is a regulatory 
region variant in the UNX homeobox that plays in maintenance and differential of 
elements of the axial skeleton.  
 
5.7 Functional Pathway Analysis 
When computing the association of the variants investigated with relevant biological 
pathways, two pathways were identified when using the programme Cytoscape the 
Advanced glycation end products (AGE or RAGE), that are signalling pathway in 
diabetic complication and the regulation of the receptor-mediated endocytosis. The 
AGE/RAGE signalling prompts the activation of various intracellular signal pathways 
such as protein kinase C, Nicotinamide Adenine Dinucleotide Phosphate (NADPH) 
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oxidase and Mitogen-Activated Protein Kinase (MAPKs) which results in NF-kappaβ 
activity. Additionally, the RAGE pathway induces the Janus Kinase/Signal Transducer 
and Activator of Transcription (JAK-STAT) mediated, hypoxia-mediated induction and 
the PI3K-Atk dependent pathways which in turn contribute to apoptosis and cell 
proliferation. The increased destruction of erythrocyte will inevitably result in increased 
intracellular material and sheared erythrocyte which can affect the function of kidneys 
resulting in kidney dysfunction (Yamagishi 2011). 
The receptor-mediated endocytosis plays a crucial role in the proximal tubule epithelial 
cells (PTECs), with regards to the reabsorption and metabolism of protein, carrier-
bound vitamins, conservation of nutrients and various substances in the glomerular 
filtrates. Disruption of this process can result in the loss of essential substances and 
development of proteinuria, which is a hallmark of kidney dysfunction. 
Analysis of the protein network pathways illustrated 8 homo-candidate gene clusters. 
The disease-associated key protein is cluster 2 with the NFKB1 gene, P19838.  The 
Nuclear Factor Kappa β Subunit 1 (NFKB1) gene has been identified as an important 
by-product of the functional pathway AGE or RAGE signalling pathway in diabetic 
complication. 
 
5.8 Influence of SCT on the APOL1 and CKD relationship 
In this cohort, a separate investigator did not previously find any association between 
APOL1 and CDK (Geard et al, 2017).  We investigated whether the result might be 
different if conditioned with the significantly influential HbAS. However, we did not find 
any significant association. This could be due to the small sample size, under power 
by the low frequency of APOL1 G1/G2 alleles (14%) in the studied population, as we 
previously postulated (Geard et al, 2017).  
 
5.9 Practical implications and research recommendation 
Most individuals that have SCT are asymptomatic and in most cases, they don’t even 
know their carrier status. The global burden of SCT, already very high in Africa is 
projected to increase, since most SCT individuals have a normal life expectancy and 
the presence of the SCT is advantageous in malaria-endemic areas particularly in 
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African countries, and also due to the global migration. SCT prevalence is also 
influenced by the increased in the life expectancy of the SCD patients who are now 
living to reproductive age in affluent countries such as USA due to improvement in 
SCD treatments and care. The study illustrated a clear association between SCT and 
CKD, that will have major implication in preventative medicine policies and practices 
in both sub-Saharan African and globally. Screening and identification of individuals 
with SCT will therefore be more actionable than previously argue, as it can help in the 
modification of lifestyle and, in some case, treatment and therapies offered to already 
symptomatic patients.  
Our study highlighted unexpected associations between SCT with HIV and 
hypertension.  Despite the selection bias and our limited sample size, the data indicate 
the need for further research in the general population, in investigating how these 
disorders influence each other, allowing the mechanism to be fully understood..  
In addition, we identified a relatively low proportion of (3/29) SNPs previously 
associated with CKD in GWAS studies among African American, Europeans, and 
Asians, indicating the urgent need to include diverse populations, specifically those in 
sun-Saharan African, so that the Polygenic risk score generated from GWAS data 
could be universally relevant. The data further indicate that there is potential to 
discovers new loci associated with CKD when investigating populations of African 
ancestry living in Africa.   
 
5.10 Limitation 
 
The recruitment was hospital-based, this could have allowed for bias enrolment of 
sicker patients which may influence the outcome of our studies. Future studies 
should aim to recruit more clinically stable individuals. 
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5.11 Conclusion and perspectives 
 
Our study illustrates a strong association between SCT and CKD, an important 
discovery that will have a major implications in medicine policies and practices in sub-
Saharan African where there is a high prevalence of SCT.  The data also has a global 
resonance, with the projected increase in the prevalence of individuals with SCT, due 
to migration and the improve life expectancy and genetic fitness of people living with 
both SCT and SCD.   
We identified a relatively low proportion of (3/29) of target SNPs positively associated 
with CKD among this group of Cameroonians. The study illustrates that the vast 
majority of targeted SNPs associated with CKD in GWAS studies in multiple 
populations including African American, Europeans, and Asians, are not relevant for 
sub-Saharan Africans, indicating the urgent need to include diverse populations, 
specifically those living in Africa, so that the Polygenic risk scores generated from 
GWAS data could be universally applicable. The data further indicate that there is 
potential to discover new loci associated with CKD when investigating populations of 
African ancestry living in Africa.   
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Appendices 
 
Appendix 1 Reagents Used 
PCR Reagents  
GOTAQ® TAQ POLYMERASE  
PROMEGA  
MADISON, WISCONSIN  
USA  
 
5X COLORLESS GOTAQ® REACTION BUFFER  
LOT NUMBER: 0000 1173 14  
PROMEGA  
MADISON, WISCONSIN  
USA  
 
DNTP MIXTURE  
LOT NUMBER: BH4601C  
TAKARA BIO INC  
NOJIHIGASHI, KUSATSU, SHIGA PREFACTURE  
JAPAN  
 
PRIMERS  
INTEGRATED DNA TECHNOLOGIES  
CORALVILLE, IOWA  
USA  
DISTRIBUTED BY: WHITEHEAD SCIENTIFIC  
CAPE TOWN, WESTERN CAPE  
SOUTH AFRICA  
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GEL ELECTROPHORESIS REAGENTS  
6X DNA LOADING DYE  
LOT NUMBER: 0011 6849  
THERMO SCIENTIFIC  
THERMOFISCHER SCIENTIFIC  
WALTHAM, MASSACHUSETTS  
USA  
 
GENERULER™ 100BP DNA LADDER  
INVITROGEN  
THERMOFISHER SCIENTIFIC  
WALTHAM, MASSACHUSETTS  
USA  
 
SEAKEM® LE AGAROSE  
LOT NUMBER: 0000 4364 71  
LONZA  
BASEL  
SWITZERLAND  
DISTRIBUTED BY: WHITEHEAD SCIENTIFIC  
CAPE TOWN, WESTERN CAPE  
SOUTH AFRICA  
 
PCR CLEAN-UP REAGENTS  
FASTAP THERMOSENSITIVE ALKALINE PHOSPHATASE  
LOT NUMBER: 0024 7986  
THERMO SCIENTIFIC  
THERMO FISCHER SCIENTIFIC  
WALTHAM, MASSACHUSETTS  
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USA  
 
EXONUCLEASE 1  
LOT NUMBER 0025 4712  
THERMO SCIENTIFIC  
THERMO FISCHER SCIENTIFIC  
WALTHAM, MASSACHUSETTS  
USA  
 
SEQUENCING REAGENTS  
BIGDYE® TERMINATOR V1.1, V3.1 5X SEQUNCING BUFFER  
LOT NUMBER 1103 200  
APPLIED BIOSYSTEMS  
THERMO FISCHER SCIENTIFIC  
WALTHAM, MASSACHUSETTS  
USA  
 
BIGDYE® TERMINATOR V3.1 CYCLE SEQUENCING RR-100  
LOT NUMBER: 1201 096  
APPLIED BIOSYSTEMS  
THERMO FISCHER SCIENTIFIC  
WALTHAM, MASSACHUSETTS  
USA 
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Appendix 2: Machines Used 
 
Thermocyclers  
BioRad T100™ Thermal Cycler  
Applied Biosystems 2720 Thermal Cycler  
Applied Biosystems GeneAmp® PCR System 9700  
 
Power Pack  
DS 5000XT DC Power Supply  
Hoefer Scientific Instruments  
 
Heating Block  
HyBaid Touchdown Thermocycler  
Scientific Group  
 
Centrifuge  
Eppendorf centrifuge 5415D  
 
Vortex  
Labnet Vortex Mixer  
Vortex Mixer Model VM-1000  
Digisystems Lab Instruments Inc 
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Appendix 3: Gel Electrophoresis Reagents 
 
SeaKem®LE Agarose 
Lonza (ME, USA) 
1% (w/v) Agarose gel (50 ml or 100 ml) 
0.5 g or 1 g agarose 
50 ml or 100 ml 1x TBE buffer 
Dissolve agarose powder by microwave heating 
Allow to cool, add 3 μl or 6 ul of Etbr and pour into a gel electrophoresis casting tray 
with a well-comb 
 
Appendix 4: PCR Amplification Reagents 
Table 12 Reagents used to amplify SCD mutation 
Reagent  Stock  Required  v=1 (μl)  
dH2O  -  -  11.9  
Taq Buffer  5X  1X  5  
dNTPs  5mM  200μM  1  
Forward 
Primer  
20μM  0.04μM  0.5  
Reverse 
Primer  
20μM  0.04μM  0.5  
Taq  5U/μl  0.02μM  0.1  
DNA  -  100ng  1  
Total  -  -  25  
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Table 1.2 Protocol used amplification. 
 Temperature 
(°C)   
Time Cycles 
Initial 
Denaturation  
95  3 Minutes  -  
Denaturation  94  30 Seconds  35X  
Primer Annealing  58.1  30 Seconds  
Elongation  72  1 Minute  
Final Elongation  72  10 Minutes  -  
 
Table 3: PCR clean-up protocol 
Reagent  V=1(μl)  
FastAP  1.0  
Exo1  0.1  
PCR Product  8.9  
Total  10.0  
Samples were incubated for 1 hour at 37°C followed by 15 minutes 72°C  
 
Appendix 5: Sequencing Conditions and Protocol  
 
Table 4: Reagents used for direct cycle (Sanger) Sequencing 
Reagents  Stock Concentration  Required Concentration  v=1(μl) 
Sabax Water  -  -  4  
Dilution Buffer  5x  -  2  
Terminator mix  -  -  1  
Primer  20 μM  0.4μM  0.5  
Cleaned PCR 
Product  
-  -  2.5  
Total  -  -  10  
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Table 5: Sequencing protocol 
 Temperature 
(°C)   
Time Cycles 
Initial 
Denaturation  
95  3 Minutes  -  
Denaturation  94  30 Seconds  35X  
Primer Annealing  58.1  30 Seconds  
Elongation  72  1 Minute  
Final Elongation  72  10 Minutes  -  
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2.5 ul of GeneRuler 100bp plus DNA Ladder was loaded onto the gels Fermentas 
(Life Sciences) USA 
 
 
